Details of the Drug Combinations

General Information of This Drug (ID: DMJV2EK)

Drug Name
Dasatinib   DMJV2EK
Synonyms
Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
Indication
Disease Entry ICD 11 Status REF
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive N.A. Approved [1]
Brain disease 8C70-8E61 Approved [1]
Central nervous system disease 8A04-8D87 Approved [1]
Chronic myelogenous leukaemia 2A20.0 Approved [2]
Chronic myeloid leukaemia 2A20 Approved [3]
Glioblastoma 2A00 Approved [1]
Leukemia N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Multiple myeloma 2A83 Phase 2 [2]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [4]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [4]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1296 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Dasatinib DC2ELHG ABIRATERONE Astrocytoma (Cell Line: U251) [5]
ABIRATERONE + Dasatinib DCDE0R2 ABIRATERONE Chronic myelogenous leukemia (Cell Line: K-562) [5]
ABIRATERONE + Dasatinib DCN3LUV ABIRATERONE Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
ABIRATERONE + Dasatinib DCS68C2 ABIRATERONE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
ABIRATERONE + Dasatinib DC640KB ABIRATERONE Glioma (Cell Line: SF-268) [5]
ABIRATERONE + Dasatinib DCLOC90 ABIRATERONE Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
ABIRATERONE + Dasatinib DCHJTLS ABIRATERONE Carcinoma (Cell Line: RXF 393) [6]
ABIRATERONE + Dasatinib DC5T2QO ABIRATERONE Adenocarcinoma (Cell Line: DU-145) [7]
ABIRATERONE + Dasatinib DCUJ17B ABIRATERONE Adenocarcinoma (Cell Line: HT29) [7]
ABIRATERONE + Dasatinib DC992H0 ABIRATERONE Large cell lung carcinoma (Cell Line: NCI-H460) [7]
ABIRATERONE + Dasatinib DCLRBVI ABIRATERONE Lung adenocarcinoma (Cell Line: HOP-62) [7]
ABIRATERONE + Dasatinib DCH4WFX ABIRATERONE Lung adenocarcinoma (Cell Line: MDA-MB-231) [7]
ABIRATERONE + Dasatinib DCNZLTP ABIRATERONE Lung adenocarcinoma (Cell Line: NCI-H522) [7]
ABIRATERONE + Dasatinib DC0N8BQ ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [7]
ABIRATERONE + Dasatinib DCTM26L ABIRATERONE Malignant melanoma (Cell Line: UACC62) [7]
ABIRATERONE + Dasatinib DC6WEI5 ABIRATERONE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
ABIRATERONE + Dasatinib DCZX0HM ABIRATERONE Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
ABIRATERONE + Dasatinib DCKA165 ABIRATERONE Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
ABIRATERONE + Dasatinib DCYM2V2 ABIRATERONE Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
ABIRATERONE + Dasatinib DCTLQXQ ABIRATERONE Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
ABIRATERONE + Dasatinib DCI80OH ABIRATERONE Prostate carcinoma (Cell Line: PC-3) [7]
Amonafide + Dasatinib DC9TZF1 Amonafide Adenocarcinoma (Cell Line: A549) [5]
Amonafide + Dasatinib DC2G669 Amonafide Adenocarcinoma (Cell Line: NCIH23) [5]
Amonafide + Dasatinib DC6HI2H Amonafide Adenocarcinoma (Cell Line: HCT116) [5]
Amonafide + Dasatinib DCMFT99 Amonafide Adenocarcinoma (Cell Line: HCC-2998) [5]
Amonafide + Dasatinib DC7CD0V Amonafide Astrocytoma (Cell Line: U251) [5]
Amonafide + Dasatinib DC3X26U Amonafide Astrocytoma (Cell Line: SNB-19) [5]
Amonafide + Dasatinib DCNB84Z Amonafide Chronic myelogenous leukemia (Cell Line: K-562) [5]
Amonafide + Dasatinib DCB4WQP Amonafide Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Amonafide + Dasatinib DCM1JVF Amonafide Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Amonafide + Dasatinib DCZN612 Amonafide Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Amonafide + Dasatinib DCA5WAJ Amonafide Glioblastoma (Cell Line: SNB-75) [5]
Amonafide + Dasatinib DCKX3A1 Amonafide Glioma (Cell Line: SF-295) [5]
Amonafide + Dasatinib DCOFN3Y Amonafide Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Amonafide + Dasatinib DCE6YPE Amonafide Lung adenocarcinoma (Cell Line: EKVX) [5]
Amonafide + Dasatinib DCHFVN5 Amonafide Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Amonafide + Dasatinib DC1KS8Y Amonafide Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Amonafide + Dasatinib DCQO2AW Amonafide Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Amonafide + Dasatinib DC2XHX7 Amonafide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Amonafide + Dasatinib DC7QLPE Amonafide Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Amonafide + Dasatinib DCMY4QQ Amonafide Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Amonafide + Dasatinib DC9BCH2 Amonafide Renal cell carcinoma (Cell Line: SN12C) [5]
Amonafide + Dasatinib DCIKQMJ Amonafide Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Anastrozole + Dasatinib DCDVARM Anastrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Anastrozole + Dasatinib DCZ9ZDW Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Anastrozole + Dasatinib DCRN6RH Anastrozole Prostate carcinoma (Cell Line: PC-3) [5]
Anastrozole + Dasatinib DCXCXRO Anastrozole Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Arfolitixorin + Dasatinib DCXLB21 Arfolitixorin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Arfolitixorin + Dasatinib DCWCPXH Arfolitixorin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Arfolitixorin + Dasatinib DCXJF1L Arfolitixorin Anaplastic large cell lymphoma (Cell Line: SR) [5]
Arfolitixorin + Dasatinib DCMYLZU Arfolitixorin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Arfolitixorin + Dasatinib DCYO92B Arfolitixorin Chronic myelogenous leukemia (Cell Line: K-562) [5]
Arfolitixorin + Dasatinib DCMHGZV Arfolitixorin Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Arfolitixorin + Dasatinib DCGWUAV Arfolitixorin Glioblastoma (Cell Line: SNB-75) [5]
Arfolitixorin + Dasatinib DCDMIZ3 Arfolitixorin Glioma (Cell Line: SF-539) [5]
Arfolitixorin + Dasatinib DCE1C68 Arfolitixorin Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Arfolitixorin + Dasatinib DCXEF8U Arfolitixorin Carcinoma (Cell Line: MCF7) [6]
Arfolitixorin + Dasatinib DC7JD92 Arfolitixorin Adenocarcinoma (Cell Line: SW-620) [7]
Arfolitixorin + Dasatinib DC829YZ Arfolitixorin Lung adenocarcinoma (Cell Line: NCI-H522) [7]
Arfolitixorin + Dasatinib DC1EV9V Arfolitixorin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Azacitidine + Dasatinib DC5WFJK Azacitidine Anaplastic large cell lymphoma (Cell Line: SR) [5]
Bafilomycin A1 + Dasatinib DCMFQ2C Bafilomycin A1 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
BIO-300 + Dasatinib DCECV2Q BIO-300 Adenocarcinoma (Cell Line: HCT116) [5]
BIO-300 + Dasatinib DCUOQHM BIO-300 Adenocarcinoma (Cell Line: HCT-15) [5]
BIO-300 + Dasatinib DCL6IUP BIO-300 Astrocytoma (Cell Line: SNB-19) [5]
BIO-300 + Dasatinib DCXT5TJ BIO-300 Chronic myelogenous leukemia (Cell Line: K-562) [5]
BIO-300 + Dasatinib DCEZ9F5 BIO-300 Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
BIO-300 + Dasatinib DCDO1LY BIO-300 Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
BIO-300 + Dasatinib DCALEWI BIO-300 Clear cell renal cell carcinoma (Cell Line: A498) [5]
BIO-300 + Dasatinib DCV3L83 BIO-300 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
BIO-300 + Dasatinib DCEQEUY BIO-300 Glioblastoma (Cell Line: SNB-75) [5]
BIO-300 + Dasatinib DC8455S BIO-300 Glioma (Cell Line: SF-295) [5]
BIO-300 + Dasatinib DCDLAT3 BIO-300 Glioma (Cell Line: SF-539) [5]
BIO-300 + Dasatinib DCTK65S BIO-300 Papillary renal cell carcinoma (Cell Line: ACHN) [5]
BIO-300 + Dasatinib DC2PFJ1 BIO-300 Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
BIO-300 + Dasatinib DCWXCSR BIO-300 Invasive ductal carcinoma (Cell Line: HS 578T) [6]
BIO-300 + Dasatinib DC6M8RY BIO-300 Invasive ductal carcinoma (Cell Line: BT-549) [6]
BIO-300 + Dasatinib DCC9OE8 BIO-300 Adenocarcinoma (Cell Line: OVCAR3) [7]
BIO-300 + Dasatinib DCFAFY8 BIO-300 Adenocarcinoma (Cell Line: NCIH23) [7]
BIO-300 + Dasatinib DCMFWE6 BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
BIO-300 + Dasatinib DCE383Q BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
BIO-300 + Dasatinib DCPF31O BIO-300 Large cell lung carcinoma (Cell Line: NCI-H460) [7]
BIO-300 + Dasatinib DCRWLX7 BIO-300 Lung adenocarcinoma (Cell Line: HOP-62) [7]
BIO-300 + Dasatinib DCG8YBB BIO-300 Lung adenocarcinoma (Cell Line: EKVX) [7]
BIO-300 + Dasatinib DC9CZZH BIO-300 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
BIO-300 + Dasatinib DCLQJR5 BIO-300 Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
BIO-300 + Dasatinib DCAR7DA BIO-300 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
BIO-300 + Dasatinib DCQWASF BIO-300 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Bleomycin + Dasatinib DC32H6Y Bleomycin Adenocarcinoma (Cell Line: SW-620) [5]
Bleomycin + Dasatinib DCQ98JY Bleomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Bleomycin + Dasatinib DC1ZPSX Bleomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Bleomycin + Dasatinib DCPOD3N Bleomycin Carcinoma (Cell Line: MCF7) [6]
Bleomycin + Dasatinib DCMMNFH Bleomycin Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Bleomycin + Dasatinib DC92WI4 Bleomycin Lung adenocarcinoma (Cell Line: NCI-H522) [7]
Bortezomib + Dasatinib DCZUWRL Bortezomib Adenocarcinoma (Cell Line: CAOV3) [5]
Bortezomib + Dasatinib DCZTWDQ Bortezomib Adenocarcinoma (Cell Line: A427) [5]
Bortezomib + Dasatinib DCCYDK6 Bortezomib Adenocarcinoma (Cell Line: NCIH520) [5]
Bortezomib + Dasatinib DCY5FDU Bortezomib Adenocarcinoma (Cell Line: DLD1) [5]
Bortezomib + Dasatinib DC2WW9S Bortezomib Adenocarcinoma (Cell Line: HT29) [5]
Bortezomib + Dasatinib DCR483O Bortezomib Amelanotic melanoma (Cell Line: A2058) [5]
Bortezomib + Dasatinib DCTIYBF Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Bortezomib + Dasatinib DCAY03H Bortezomib Germ cell tumour (Cell Line: PA1) [5]
Bortezomib + Dasatinib DCF4AZD Bortezomib Malignant melanoma (Cell Line: A375) [5]
Bortezomib + Dasatinib DCUJNZ5 Bortezomib Malignant melanoma (Cell Line: UACC62) [5]
Bortezomib + Dasatinib DCXR7TG Bortezomib Mesothelioma (Cell Line: MSTO) [5]
Bortezomib + Dasatinib DC7F6QB Bortezomib Non small cell carcinoma (Cell Line: SKMES1) [5]
Bortezomib + Dasatinib DC6B4RU Bortezomib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Bortezomib + Dasatinib DC5UFKH Bortezomib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Bortezomib + Dasatinib DCHN51N Bortezomib Breast carcinoma (Cell Line: ZR751) [6]
Bortezomib + Dasatinib DCAK9FB Bortezomib Breast carcinoma (Cell Line: KPL1) [6]
Bortezomib + Dasatinib DC7KDDE Bortezomib Breast carcinoma (Cell Line: OCUBM) [6]
Bortezomib + Dasatinib DCJQYPB Bortezomib Carcinoma (Cell Line: MDAMB436) [6]
Bortezomib + Dasatinib DCB2I2X Bortezomib Colon adenocarcinoma (Cell Line: LOVO) [6]
Bortezomib + Dasatinib DCERSH1 Bortezomib Colon carcinoma (Cell Line: RKO) [6]
Bortezomib + Dasatinib DCXPHMD Bortezomib Rectal adenocarcinoma (Cell Line: SW837) [6]
CA4P + Dasatinib DCIOTLP CA4P Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Cabazitaxel + Dasatinib DC7HDLB Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [5]
Cabazitaxel + Dasatinib DCFJ2GE Cabazitaxel Adenocarcinoma (Cell Line: SW-620) [5]
Cabazitaxel + Dasatinib DCZ6N1D Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [5]
Cabazitaxel + Dasatinib DC74QVK Cabazitaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Cabazitaxel + Dasatinib DC8FY2D Cabazitaxel Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Cabazitaxel + Dasatinib DCQ7S2I Cabazitaxel Glioma (Cell Line: SF-268) [5]
Cabazitaxel + Dasatinib DCFGUCB Cabazitaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Cabazitaxel + Dasatinib DCJC3JS Cabazitaxel Lung adenocarcinoma (Cell Line: HOP-62) [5]
Cabazitaxel + Dasatinib DCOXT3V Cabazitaxel Malignant melanoma (Cell Line: LOX IMVI) [5]
Cabazitaxel + Dasatinib DCKAL2E Cabazitaxel Melanoma (Cell Line: MALME-3M) [5]
Cabazitaxel + Dasatinib DCHDUIK Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Cabazitaxel + Dasatinib DCU7FYX Cabazitaxel Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Cabazitaxel + Dasatinib DCYN7AK Cabazitaxel Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Cabazitaxel + Dasatinib DC9D4AD Cabazitaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Cabazitaxel + Dasatinib DC0WDTN Cabazitaxel Renal cell carcinoma (Cell Line: UO-31) [5]
Crizotinib + Dasatinib DC7CM9K Crizotinib Adenocarcinoma (Cell Line: DU-145) [5]
Crizotinib + Dasatinib DC8GWRW Crizotinib Adenocarcinoma (Cell Line: A549) [5]
Crizotinib + Dasatinib DC74W5D Crizotinib Adenocarcinoma (Cell Line: HT29) [5]
Crizotinib + Dasatinib DCCILNB Crizotinib Astrocytoma (Cell Line: U251) [5]
Crizotinib + Dasatinib DCEHK4S Crizotinib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Crizotinib + Dasatinib DC84GSH Crizotinib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Crizotinib + Dasatinib DCRUZA9 Crizotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Crizotinib + Dasatinib DC43WUP Crizotinib Glioma (Cell Line: SF-268) [5]
Crizotinib + Dasatinib DCUR88V Crizotinib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Crizotinib + Dasatinib DC7ZT0X Crizotinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Crizotinib + Dasatinib DCMZ3OV Crizotinib Lung adenocarcinoma (Cell Line: EKVX) [5]
Crizotinib + Dasatinib DCWFOK7 Crizotinib Lung adenocarcinoma (Cell Line: HOP-62) [5]
Crizotinib + Dasatinib DCYXX70 Crizotinib Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Crizotinib + Dasatinib DC8TRHK Crizotinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Crizotinib + Dasatinib DCJ4FZG Crizotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Crizotinib + Dasatinib DCY4KUE Crizotinib Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Crizotinib + Dasatinib DCV3QWN Crizotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Crizotinib + Dasatinib DC3H4CV Crizotinib Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Crizotinib + Dasatinib DCP4R8G Crizotinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Crizotinib + Dasatinib DCDG694 Crizotinib Prostate carcinoma (Cell Line: PC-3) [5]
Crizotinib + Dasatinib DCN96HJ Crizotinib Invasive ductal carcinoma (Cell Line: T-47D) [6]
Cyclophosphamide + Dasatinib DCAZ3FI Cyclophosphamide Adenocarcinoma (Cell Line: NCIH520) [5]
Cyclophosphamide + Dasatinib DCEM6O5 Cyclophosphamide Adenocarcinoma (Cell Line: COLO320DM) [5]
Cyclophosphamide + Dasatinib DC6VOZT Cyclophosphamide Adenocarcinoma (Cell Line: SW-620) [5]
Cyclophosphamide + Dasatinib DC9NQ49 Cyclophosphamide Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Cyclophosphamide + Dasatinib DC2AFQV Cyclophosphamide Malignant melanoma (Cell Line: SKMEL30) [5]
Cyclophosphamide + Dasatinib DC37J6G Cyclophosphamide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Cyclophosphamide + Dasatinib DCD4ZWN Cyclophosphamide Prostate carcinoma (Cell Line: VCAP) [5]
Cyclophosphamide + Dasatinib DC5WTCJ Cyclophosphamide Breast carcinoma (Cell Line: ZR751) [6]
Cyclophosphamide + Dasatinib DC4F547 Cyclophosphamide Carcinoma (Cell Line: EFM192B) [6]
Dacarbazine + Dasatinib DCR0L77 Dacarbazine Adenocarcinoma (Cell Line: NCIH23) [5]
Dacarbazine + Dasatinib DCL0GMY Dacarbazine Adenocarcinoma (Cell Line: HCC-2998) [5]
Dacarbazine + Dasatinib DC9PVSV Dacarbazine Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Dacarbazine + Dasatinib DCJ9JO4 Dacarbazine Anaplastic large cell lymphoma (Cell Line: SR) [5]
Dacarbazine + Dasatinib DCC4KKJ Dacarbazine Astrocytoma (Cell Line: SNB-19) [5]
Dacarbazine + Dasatinib DCXCQT1 Dacarbazine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Dacarbazine + Dasatinib DCY3C1J Dacarbazine Chronic myelogenous leukemia (Cell Line: K-562) [5]
Dacarbazine + Dasatinib DCHEV1I Dacarbazine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Dacarbazine + Dasatinib DCHUSLQ Dacarbazine Glioma (Cell Line: SF-539) [5]
Dacarbazine + Dasatinib DC987D4 Dacarbazine Malignant melanoma (Cell Line: UACC62) [5]
Dacarbazine + Dasatinib DCAU19Q Dacarbazine Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Dactinomycin + Dasatinib DCZQ2DI Dactinomycin Carcinoma (Cell Line: RXF 393) [6]
Dactinomycin + Dasatinib DC73NE6 Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [7]
Dactinomycin + Dasatinib DC8GMZP Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Dactinomycin + Dasatinib DC84UHM Dactinomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Dasatinib + Pentostatin DCNQ4DB Pentostatin Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + Pentostatin DC4J2C0 Pentostatin Adenocarcinoma (Cell Line: HCT116) [5]
Dasatinib + Pentostatin DC8J1JR Pentostatin Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Dasatinib + Pentostatin DCMJA8Q Pentostatin Glioma (Cell Line: SF-539) [5]
Dasatinib + Fulvestrant DCTAQOU Fulvestrant Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + Fulvestrant DCWQTIR Fulvestrant Amelanotic melanoma (Cell Line: M14) [5]
Dasatinib + Fulvestrant DC96B9K Fulvestrant Glioma (Cell Line: SF-268) [5]
Dasatinib + Fulvestrant DC7S0GY Fulvestrant Glioma (Cell Line: SF-539) [5]
Dasatinib + Fulvestrant DC69PKF Fulvestrant Glioma (Cell Line: SF-295) [5]
Dasatinib + Fulvestrant DCEMG8S Fulvestrant Malignant melanoma (Cell Line: LOX IMVI) [5]
Dasatinib + Fulvestrant DCAEY0U Fulvestrant Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Dasatinib + Fulvestrant DCPLXRI Fulvestrant Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Dasatinib + Buparlisib DCT815U Buparlisib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Dasatinib + Ixabepilone DCZ9PFL Ixabepilone Adenocarcinoma (Cell Line: A549) [5]
Dasatinib + Ixabepilone DCUET4E Ixabepilone Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Dasatinib + Ixabepilone DCA7FZO Ixabepilone Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Dasatinib + Ixabepilone DC6X78B Ixabepilone Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Dasatinib + Lapatinib DCPOG9C Lapatinib Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + Lapatinib DCXGD6U Lapatinib Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + Lapatinib DCA86OR Lapatinib Adenocarcinoma (Cell Line: HCT-15) [5]
Dasatinib + Lapatinib DC7CHFV Lapatinib Astrocytoma (Cell Line: SNB-19) [5]
Dasatinib + Lapatinib DCHVRP5 Lapatinib Glioma (Cell Line: SF-539) [5]
Dasatinib + Lapatinib DCAFJY9 Lapatinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Dasatinib + Lapatinib DC0KQEI Lapatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Dasatinib + Lapatinib DCY4TSW Lapatinib Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Dasatinib + Lapatinib DCF98BX Lapatinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Dasatinib + JQ1 DCQBYOJ JQ1 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Dasatinib + Cyclophosphamide DCGPRW4 Cyclophosphamide Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + Cyclophosphamide DCYQILW Cyclophosphamide Adenocarcinoma (Cell Line: HCT116) [5]
Dasatinib + Cyclophosphamide DCKRR63 Cyclophosphamide Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Dasatinib + Cyclophosphamide DC39K6V Cyclophosphamide High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Dasatinib + Cyclophosphamide DCG6J7C Cyclophosphamide Melanoma (Cell Line: UACC-257) [5]
Dasatinib + Cyclophosphamide DCCBYFQ Cyclophosphamide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Dasatinib + Panobinostat DCHXRLV Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Dasatinib + Arsenic trioxide DCOJC57 Arsenic trioxide Adenocarcinoma (Cell Line: DU-145) [5]
Dasatinib + Arsenic trioxide DC32A0S Arsenic trioxide Anaplastic large cell lymphoma (Cell Line: SR) [5]
Dasatinib + Arsenic trioxide DCI4O6B Arsenic trioxide Melanoma (Cell Line: UACC-257) [5]
Dasatinib + RTB101 DCOLGRM RTB101 Adenocarcinoma (Cell Line: CAOV3) [5]
Dasatinib + RTB101 DCSN06J RTB101 Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + RTB101 DCZQMC8 RTB101 Adenocarcinoma (Cell Line: A427) [5]
Dasatinib + RTB101 DC9CHXG RTB101 Adenocarcinoma (Cell Line: NCIH1650) [5]
Dasatinib + RTB101 DC04LIT RTB101 Adenocarcinoma (Cell Line: NCIH23) [5]
Dasatinib + RTB101 DC6XV2C RTB101 Adenocarcinoma (Cell Line: NCIH520) [5]
Dasatinib + RTB101 DCQEUPS RTB101 Adenocarcinoma (Cell Line: DLD1) [5]
Dasatinib + RTB101 DCRXVQ6 RTB101 Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + RTB101 DCN5S4P RTB101 Amelanotic melanoma (Cell Line: A2058) [5]
Dasatinib + RTB101 DCAMJ71 RTB101 Germ cell tumour (Cell Line: PA1) [5]
Dasatinib + RTB101 DCZVTEJ RTB101 Malignant melanoma (Cell Line: A375) [5]
Dasatinib + RTB101 DCWNL8S RTB101 Malignant melanoma (Cell Line: RPMI7951) [5]
Dasatinib + RTB101 DCR87GM RTB101 Malignant melanoma (Cell Line: UACC62) [5]
Dasatinib + RTB101 DC5I59J RTB101 Mesothelioma (Cell Line: MSTO) [5]
Dasatinib + RTB101 DC7TF78 RTB101 Non small cell carcinoma (Cell Line: SKMES1) [5]
Dasatinib + RTB101 DCTKV4P RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Dasatinib + RTB101 DCC7Q3P RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Dasatinib + RTB101 DC1TH0X RTB101 Prostate carcinoma (Cell Line: LNCAP) [5]
Dasatinib + SCH-900776 DC83U6D SCH-900776 Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + SCH-900776 DCIMXI7 SCH-900776 Adenocarcinoma (Cell Line: A427) [5]
Dasatinib + SCH-900776 DCZRJON SCH-900776 Adenocarcinoma (Cell Line: NCIH1650) [5]
Dasatinib + SCH-900776 DCTZJLJ SCH-900776 Adenocarcinoma (Cell Line: NCIH23) [5]
Dasatinib + SCH-900776 DC9179G SCH-900776 Adenocarcinoma (Cell Line: NCIH520) [5]
Dasatinib + SCH-900776 DCBP533 SCH-900776 Adenocarcinoma (Cell Line: DLD1) [5]
Dasatinib + SCH-900776 DCVO5K2 SCH-900776 Adenocarcinoma (Cell Line: HCT116) [5]
Dasatinib + SCH-900776 DCAFKRT SCH-900776 Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + SCH-900776 DCTDXXY SCH-900776 Adenocarcinoma (Cell Line: SW-620) [5]
Dasatinib + SCH-900776 DC15CBA SCH-900776 Amelanotic melanoma (Cell Line: A2058) [5]
Dasatinib + SCH-900776 DC7YHAC SCH-900776 Germ cell tumour (Cell Line: PA1) [5]
Dasatinib + SCH-900776 DC9JYRN SCH-900776 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Dasatinib + SCH-900776 DCKKH4K SCH-900776 Malignant melanoma (Cell Line: A375) [5]
Dasatinib + SCH-900776 DCRLZTX SCH-900776 Malignant melanoma (Cell Line: HT144) [5]
Dasatinib + SCH-900776 DCUPE08 SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [5]
Dasatinib + SCH-900776 DCRM1ML SCH-900776 Malignant melanoma (Cell Line: UACC62) [5]
Dasatinib + SCH-900776 DCZNUF7 SCH-900776 Mesothelioma (Cell Line: MSTO) [5]
Dasatinib + SCH-900776 DCVZKCG SCH-900776 Non small cell carcinoma (Cell Line: SKMES1) [5]
Dasatinib + SCH-900776 DCFC4EK SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Dasatinib + SCH-900776 DC1HGCW SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Dasatinib + SCH-900776 DCSN5X9 SCH-900776 Prostate carcinoma (Cell Line: VCAP) [5]
Dasatinib + Plicamycin DCJEC96 Plicamycin Adenocarcinoma (Cell Line: DU-145) [5]
Dasatinib + Plicamycin DC0BMH6 Plicamycin Adenocarcinoma (Cell Line: NCIH23) [5]
Dasatinib + Plicamycin DCNZE1F Plicamycin Adenocarcinoma (Cell Line: HCT-15) [5]
Dasatinib + Plicamycin DCQPC2M Plicamycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Dasatinib + Plicamycin DC57V5D Plicamycin Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Dasatinib + Plicamycin DCUE413 Plicamycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Dasatinib + Plicamycin DCVK73W Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Dasatinib + Plicamycin DC4NIEE Plicamycin Malignant melanoma (Cell Line: UACC62) [5]
Dasatinib + Plicamycin DC1CDGN Plicamycin Melanoma (Cell Line: SK-MEL-2) [5]
Dasatinib + Plicamycin DCVO3DR Plicamycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Dasatinib + Plicamycin DCUPFG2 Plicamycin Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Dasatinib + Triapine DCWPOPN Triapine Anaplastic large cell lymphoma (Cell Line: SR) [5]
Dasatinib + Triapine DC592YL Triapine Astrocytoma (Cell Line: U251) [5]
Dasatinib + 10-hydroxycamptothecin DC2RPVM 10-hydroxycamptothecin Adenocarcinoma (Cell Line: CAOV3) [5]
Dasatinib + 10-hydroxycamptothecin DCK7RWP 10-hydroxycamptothecin Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + 10-hydroxycamptothecin DCRDUDN 10-hydroxycamptothecin Adenocarcinoma (Cell Line: A427) [5]
Dasatinib + 10-hydroxycamptothecin DCLLG0W 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH1650) [5]
Dasatinib + 10-hydroxycamptothecin DCB2666 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH23) [5]
Dasatinib + 10-hydroxycamptothecin DCH8UPR 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH520) [5]
Dasatinib + 10-hydroxycamptothecin DCLRNAG 10-hydroxycamptothecin Adenocarcinoma (Cell Line: DLD1) [5]
Dasatinib + 10-hydroxycamptothecin DCKG2HH 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + 10-hydroxycamptothecin DCGR1TG 10-hydroxycamptothecin Amelanotic melanoma (Cell Line: A2058) [5]
Dasatinib + 10-hydroxycamptothecin DCBGU6J 10-hydroxycamptothecin Germ cell tumour (Cell Line: PA1) [5]
Dasatinib + 10-hydroxycamptothecin DCNG4C6 10-hydroxycamptothecin Malignant melanoma (Cell Line: A375) [5]
Dasatinib + 10-hydroxycamptothecin DC06N4Z 10-hydroxycamptothecin Malignant melanoma (Cell Line: RPMI7951) [5]
Dasatinib + 10-hydroxycamptothecin DCV91GT 10-hydroxycamptothecin Malignant melanoma (Cell Line: UACC62) [5]
Dasatinib + 10-hydroxycamptothecin DCE4WD5 10-hydroxycamptothecin Mesothelioma (Cell Line: MSTO) [5]
Dasatinib + 10-hydroxycamptothecin DCTC73M 10-hydroxycamptothecin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Dasatinib + 10-hydroxycamptothecin DCE96H4 10-hydroxycamptothecin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Dasatinib + 10-hydroxycamptothecin DCXB44A 10-hydroxycamptothecin Prostate carcinoma (Cell Line: VCAP) [5]
Dasatinib + Topetecan DCE109I Topetecan Chronic myelogenous leukemia (Cell Line: K-562) [5]
Dasatinib + Pralatrexate DCIGJKO Pralatrexate Adenocarcinoma (Cell Line: DU-145) [5]
Dasatinib + Pralatrexate DCC1WWM Pralatrexate Adenocarcinoma (Cell Line: HCT-15) [5]
Dasatinib + Pralatrexate DCPWIP9 Pralatrexate Glioma (Cell Line: SF-539) [5]
Dasatinib + Pralatrexate DC2SIW1 Pralatrexate Melanoma (Cell Line: UACC-257) [5]
Dasatinib + SNX-2112 DCJGEO0 SNX-2112 Adenocarcinoma (Cell Line: NCIH1650) [5]
Dasatinib + SNX-2112 DCGX4EJ SNX-2112 Adenocarcinoma (Cell Line: NCIH23) [5]
Dasatinib + SNX-2112 DCVOR4A SNX-2112 Adenocarcinoma (Cell Line: COLO320DM) [5]
Dasatinib + SNX-2112 DC5R3B7 SNX-2112 Adenocarcinoma (Cell Line: DLD1) [5]
Dasatinib + SNX-2112 DC7KPKJ SNX-2112 Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + SNX-2112 DCA08EM SNX-2112 Germ cell tumour (Cell Line: PA1) [5]
Dasatinib + SNX-2112 DCOQUI3 SNX-2112 Malignant melanoma (Cell Line: A375) [5]
Dasatinib + SNX-2112 DCXI0GW SNX-2112 Malignant melanoma (Cell Line: RPMI7951) [5]
Dasatinib + SNX-2112 DCWER7T SNX-2112 Mesothelioma (Cell Line: MSTO) [5]
Dasatinib + SNX-2112 DCJUVYJ SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [5]
Dasatinib + SNX-2112 DCQWO09 SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Dasatinib + SNX-2112 DCCG47Z SNX-2112 Prostate carcinoma (Cell Line: LNCAP) [5]
Dasatinib + SNX-2112 DCNGCA2 SNX-2112 Prostate carcinoma (Cell Line: VCAP) [5]
Dasatinib + Selumetinib DCIBBV1 Selumetinib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Dasatinib + Cantharidin DCC3DJ7 Cantharidin Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Dasatinib + Terameprocol DCULAIE Terameprocol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Dasatinib + Terameprocol DCSRMIL Terameprocol Glioma (Cell Line: SF-539) [5]
Dasatinib + Terameprocol DCRKBPV Terameprocol Glioma (Cell Line: SF-295) [5]
Dasatinib + Terameprocol DCCHPFT Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Dasatinib + Terameprocol DCD9B0R Terameprocol Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Dasatinib + SCH 727965 DCP08WO SCH 727965 Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + SCH 727965 DCM3CEV SCH 727965 Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + SCH 727965 DCDNYTN SCH 727965 Adenocarcinoma (Cell Line: HCT116) [5]
Dasatinib + SCH 727965 DCEN55L SCH 727965 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Dasatinib + SCH 727965 DCDK1OO SCH 727965 Astrocytoma (Cell Line: SNB-19) [5]
Dasatinib + SCH 727965 DCPMLYG SCH 727965 Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Dasatinib + SCH 727965 DC1H6RN SCH 727965 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Dasatinib + SCH 727965 DC6JOAS SCH 727965 Lung adenocarcinoma (Cell Line: EKVX) [5]
Dasatinib + SCH 727965 DCM8WNN SCH 727965 Malignant melanoma (Cell Line: LOX IMVI) [5]
Dasatinib + SCH 727965 DCP9VEV SCH 727965 Malignant melanoma (Cell Line: UACC62) [5]
Dasatinib + SCH 727965 DCCECJY SCH 727965 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Dasatinib + SCH 727965 DCA4AIV SCH 727965 Renal cell carcinoma (Cell Line: SN12C) [5]
Dasatinib + Ifosfamide DCEUMWU Ifosfamide Adenocarcinoma (Cell Line: HCT116) [5]
Dasatinib + Ifosfamide DCFF413 Ifosfamide Amelanotic melanoma (Cell Line: M14) [5]
Dasatinib + Ifosfamide DCLARUI Ifosfamide Glioma (Cell Line: SF-295) [5]
Dasatinib + Ifosfamide DCV75TB Ifosfamide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Dasatinib + Plinabulin DCV3AMU Plinabulin Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Dasatinib + THAPSIGARGIN DCYCJ4J THAPSIGARGIN Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Dasatinib + THAPSIGARGIN DC091YZ THAPSIGARGIN Primitive neuroectodermal tumor (Cell Line: TC-32) [5]
Dasatinib + SNS-032 DCW0PVU SNS-032 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Dasatinib + Bendamustine hydrochloride DCSKINI Bendamustine hydrochloride Adenocarcinoma (Cell Line: A549) [5]
Dasatinib + Bendamustine hydrochloride DC1MHPS Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT-15) [5]
Dasatinib + Bendamustine hydrochloride DC33B4K Bendamustine hydrochloride Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + Bendamustine hydrochloride DCWV6AF Bendamustine hydrochloride Chronic myelogenous leukemia (Cell Line: K-562) [5]
Dasatinib + Bendamustine hydrochloride DCCCZMD Bendamustine hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Dasatinib + Bendamustine hydrochloride DCIMMNI Bendamustine hydrochloride Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Dasatinib + Bendamustine hydrochloride DC0OBOK Bendamustine hydrochloride Malignant melanoma (Cell Line: UACC62) [5]
Dasatinib + Bendamustine hydrochloride DCXFRCQ Bendamustine hydrochloride Melanoma (Cell Line: SK-MEL-2) [5]
Dasatinib + Mitomycin DCTLEOJ Mitomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Dasatinib + Mitomycin DCDXJHZ Mitomycin Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Dasatinib + Mitomycin DCJIONV Mitomycin Diffuse large B cell lymphoma (Cell Line: TMD8) [5]
Dasatinib + Mitomycin DCW1CA0 Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Dasatinib + Altretamine DCMM61S Altretamine Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + Altretamine DC8R8VO Altretamine Adenocarcinoma (Cell Line: SW-620) [5]
Dasatinib + Altretamine DCJBQ03 Altretamine Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Dasatinib + Altretamine DCD81AO Altretamine Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Dasatinib + Altretamine DCVF3CU Altretamine Glioma (Cell Line: SF-295) [5]
Dasatinib + Altretamine DCR799O Altretamine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Dasatinib + Altretamine DCEQYNG Altretamine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Dasatinib + Altretamine DCKMPLU Altretamine Lung adenocarcinoma (Cell Line: HOP-62) [5]
Dasatinib + Altretamine DCJIRL0 Altretamine Melanoma (Cell Line: UACC-257) [5]
Dasatinib + Altretamine DC8OYLH Altretamine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Dasatinib + AS602868 DCWQB98 AS602868 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Dasatinib + Ridaforolimus DCVT8JT Ridaforolimus Adenocarcinoma (Cell Line: CAOV3) [5]
Dasatinib + Ridaforolimus DC5RNED Ridaforolimus Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + Ridaforolimus DC6XTB6 Ridaforolimus Adenocarcinoma (Cell Line: NCIH1650) [5]
Dasatinib + Ridaforolimus DCTSFQZ Ridaforolimus Adenocarcinoma (Cell Line: NCIH23) [5]
Dasatinib + Ridaforolimus DCNQQZ8 Ridaforolimus Adenocarcinoma (Cell Line: NCIH520) [5]
Dasatinib + Ridaforolimus DC6RJSL Ridaforolimus Adenocarcinoma (Cell Line: DLD1) [5]
Dasatinib + Ridaforolimus DCU1O9M Ridaforolimus Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + Ridaforolimus DCA0YNT Ridaforolimus Adenocarcinoma (Cell Line: SW-620) [5]
Dasatinib + Ridaforolimus DCB3VLK Ridaforolimus Amelanotic melanoma (Cell Line: A2058) [5]
Dasatinib + Ridaforolimus DCW5L9G Ridaforolimus Germ cell tumour (Cell Line: PA1) [5]
Dasatinib + Ridaforolimus DCPOD3J Ridaforolimus Malignant melanoma (Cell Line: A375) [5]
Dasatinib + Ridaforolimus DC03VM6 Ridaforolimus Mesothelioma (Cell Line: MSTO) [5]
Dasatinib + Ridaforolimus DCZGIYU Ridaforolimus Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Dasatinib + Ridaforolimus DC9JV3I Ridaforolimus Prostate carcinoma (Cell Line: LNCAP) [5]
Dasatinib + TEM DCR8B8J TEM Astrocytoma (Cell Line: U251) [5]
Dasatinib + TEM DC9507V TEM Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Dasatinib + TEM DCAANJX TEM Melanoma (Cell Line: MALME-3M) [5]
Dasatinib + MK-4827 DCHC0JC MK-4827 Adenocarcinoma (Cell Line: CAOV3) [5]
Dasatinib + MK-4827 DCA3INL MK-4827 Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + MK-4827 DC71ZOK MK-4827 Adenocarcinoma (Cell Line: A427) [5]
Dasatinib + MK-4827 DC2OKE7 MK-4827 Adenocarcinoma (Cell Line: NCIH1650) [5]
Dasatinib + MK-4827 DCQZGOQ MK-4827 Adenocarcinoma (Cell Line: NCIH23) [5]
Dasatinib + MK-4827 DC7IWC1 MK-4827 Adenocarcinoma (Cell Line: NCIH520) [5]
Dasatinib + MK-4827 DCDK6WE MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [5]
Dasatinib + MK-4827 DC6RTRN MK-4827 Adenocarcinoma (Cell Line: DLD1) [5]
Dasatinib + MK-4827 DC8BOWZ MK-4827 Adenocarcinoma (Cell Line: HCT116) [5]
Dasatinib + MK-4827 DCNGNT5 MK-4827 Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + MK-4827 DCQEH0Q MK-4827 Adenocarcinoma (Cell Line: SW-620) [5]
Dasatinib + MK-4827 DCBYIDT MK-4827 Amelanotic melanoma (Cell Line: A2058) [5]
Dasatinib + MK-4827 DC4HWYV MK-4827 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Dasatinib + MK-4827 DC2ONGT MK-4827 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Dasatinib + MK-4827 DC2IELE MK-4827 Malignant melanoma (Cell Line: A375) [5]
Dasatinib + MK-4827 DCRYUOU MK-4827 Malignant melanoma (Cell Line: SKMEL30) [5]
Dasatinib + MK-4827 DCEURGT MK-4827 Mesothelioma (Cell Line: MSTO) [5]
Dasatinib + MK-4827 DCJ79HU MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [5]
Dasatinib + MK-4827 DC75F21 MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Dasatinib + MK-4827 DC2RTVB MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Dasatinib + MK-4827 DCGKMMY MK-4827 Prostate carcinoma (Cell Line: LNCAP) [5]
Dasatinib + MK-4827 DC1JYPP MK-4827 Prostate carcinoma (Cell Line: VCAP) [5]
Dasatinib + Idarubicin DCC4HA2 Idarubicin Glioblastoma? (Cell Line: T98G) [5]
Dasatinib + Lomustine DC0ODQQ Lomustine Adenocarcinoma (Cell Line: A427) [5]
Dasatinib + Lomustine DCGS4BW Lomustine Amelanotic melanoma (Cell Line: A2058) [5]
Dasatinib + Lomustine DC16EWQ Lomustine Germ cell tumour (Cell Line: PA1) [5]
Dasatinib + Lomustine DCDB22X Lomustine Mesothelioma (Cell Line: MSTO) [5]
Dasatinib + Lomustine DCH22YG Lomustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Dasatinib + Lomustine DCNYORB Lomustine Prostate carcinoma (Cell Line: LNCAP) [5]
Dasatinib + Ciclopirox DCNQHSF Ciclopirox Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Dasatinib + ABT-263 DC39A52 ABT-263 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Dasatinib + Bleomycin DCXDGY5 Bleomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Dasatinib + Bleomycin DCUK7P2 Bleomycin Astrocytoma (Cell Line: U251) [5]
Dasatinib + Bleomycin DCA252S Bleomycin Malignant melanoma (Cell Line: LOX IMVI) [5]
Dasatinib + Bortezomib DCL93Y8 Bortezomib Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + Bortezomib DC03ANZ Bortezomib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Dasatinib + Mebendazole DC43CDY Mebendazole Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Dasatinib + IMD-0354 DCRIUPZ IMD-0354 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Dasatinib + Valrubicin DC8J3DO Valrubicin Adenocarcinoma (Cell Line: HCT116) [5]
Dasatinib + Valrubicin DCBO70A Valrubicin Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + Valrubicin DCFDTNK Valrubicin Adenocarcinoma (Cell Line: HCT-15) [5]
Dasatinib + Valrubicin DCHFNH6 Valrubicin Amelanotic melanoma (Cell Line: M14) [5]
Dasatinib + Valrubicin DCR63ZN Valrubicin Astrocytoma (Cell Line: U251) [5]
Dasatinib + Valrubicin DCREQZT Valrubicin Astrocytoma (Cell Line: SNB-19) [5]
Dasatinib + Valrubicin DCN2OIS Valrubicin Chronic myelogenous leukemia (Cell Line: K-562) [5]
Dasatinib + Valrubicin DCRAUMN Valrubicin Clear cell renal cell carcinoma (Cell Line: A498) [5]
Dasatinib + Valrubicin DCWEKXL Valrubicin Glioma (Cell Line: SF-539) [5]
Dasatinib + Valrubicin DCF2D26 Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Dasatinib + Valrubicin DCZOGVH Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Dasatinib + Valrubicin DC41ISQ Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Dasatinib + Valrubicin DCM7M63 Valrubicin Lung adenocarcinoma (Cell Line: HOP-62) [5]
Dasatinib + Valrubicin DCO0RKG Valrubicin Malignant melanoma (Cell Line: UACC62) [5]
Dasatinib + Valrubicin DCZ6GRM Valrubicin Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Dasatinib + Valrubicin DCPJWME Valrubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Dasatinib + Valrubicin DCFPLL0 Valrubicin Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Dasatinib + Valrubicin DC44Y0O Valrubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Dasatinib + Valrubicin DCKG5OU Valrubicin Prostate carcinoma (Cell Line: PC-3) [5]
Dasatinib + Valrubicin DC1W56U Valrubicin Renal cell carcinoma (Cell Line: SN12C) [5]
Dasatinib + GSK525762 DC9PXAC GSK525762 Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + GSK525762 DC3VYP4 GSK525762 Adenocarcinoma (Cell Line: A427) [5]
Dasatinib + GSK525762 DC2KXXR GSK525762 Adenocarcinoma (Cell Line: NCIH520) [5]
Dasatinib + GSK525762 DCEV0T7 GSK525762 Adenocarcinoma (Cell Line: COLO320DM) [5]
Dasatinib + GSK525762 DCYLNLW GSK525762 Adenocarcinoma (Cell Line: SW-620) [5]
Dasatinib + GSK525762 DCW0S9D GSK525762 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Dasatinib + GSK525762 DC69VCG GSK525762 Mesothelioma (Cell Line: MSTO) [5]
Dasatinib + GSK525762 DC44IC1 GSK525762 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Dasatinib + GSK525762 DCUAAV3 GSK525762 Prostate carcinoma (Cell Line: VCAP) [5]
Dasatinib + BMS-754807 DCYRJWG BMS-754807 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Dasatinib + BMS-754807 DCIDGK1 BMS-754807 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Dasatinib + BMS-754807 DCY1XB7 BMS-754807 Primitive neuroectodermal tumor (Cell Line: TC-32) [5]
Dasatinib + Cisplatin DCJX7ZN Cisplatin Adenocarcinoma (Cell Line: A549) [5]
Dasatinib + Cisplatin DCLKOS0 Cisplatin Amelanotic melanoma (Cell Line: M14) [5]
Dasatinib + Cisplatin DCQH03G Cisplatin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Dasatinib + Cisplatin DCJ0RJA Cisplatin Chronic myelogenous leukemia (Cell Line: K-562) [5]
Dasatinib + Cisplatin DCTBFUK Cisplatin Lung adenocarcinoma (Cell Line: HOP-62) [5]
Dasatinib + Cisplatin DCSJS6R Cisplatin Melanoma (Cell Line: MALME-3M) [5]
Dasatinib + Chlorambucil DCW0Z2P Chlorambucil Amelanotic melanoma (Cell Line: M14) [5]
Dasatinib + Chlorambucil DCDV21Q Chlorambucil Glioma (Cell Line: SF-295) [5]
Dasatinib + Chlorambucil DCEIM4L Chlorambucil High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Dasatinib + Chlorambucil DCN8W2S Chlorambucil Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Dasatinib + PF-04691502 DCASYJS PF-04691502 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Dasatinib + PF-04691502 DC3BJQ0 PF-04691502 Primitive neuroectodermal tumor (Cell Line: TC-32) [5]
Dasatinib + Sorafenib DCXSWSZ Sorafenib Adenocarcinoma (Cell Line: CAOV3) [5]
Dasatinib + Sorafenib DC9X8QK Sorafenib Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + Sorafenib DCCCU9Q Sorafenib Adenocarcinoma (Cell Line: A427) [5]
Dasatinib + Sorafenib DCQ7GXO Sorafenib Adenocarcinoma (Cell Line: NCIH1650) [5]
Dasatinib + Sorafenib DCO14B8 Sorafenib Adenocarcinoma (Cell Line: NCIH23) [5]
Dasatinib + Sorafenib DCE1S15 Sorafenib Adenocarcinoma (Cell Line: NCIH520) [5]
Dasatinib + Sorafenib DCJEW73 Sorafenib Adenocarcinoma (Cell Line: DLD1) [5]
Dasatinib + Sorafenib DCVS3H6 Sorafenib Adenocarcinoma (Cell Line: HCT116) [5]
Dasatinib + Sorafenib DCLLEET Sorafenib Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + Sorafenib DCQNDQ8 Sorafenib Adenocarcinoma (Cell Line: SW-620) [5]
Dasatinib + Sorafenib DCMZXQH Sorafenib Amelanotic melanoma (Cell Line: A2058) [5]
Dasatinib + Sorafenib DCDEG3K Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Dasatinib + Sorafenib DC85O0I Sorafenib Germ cell tumour (Cell Line: PA1) [5]
Dasatinib + Sorafenib DCVHR6B Sorafenib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Dasatinib + Sorafenib DCOB7GO Sorafenib Malignant melanoma (Cell Line: A375) [5]
Dasatinib + Sorafenib DCY3XRM Sorafenib Malignant melanoma (Cell Line: HT144) [5]
Dasatinib + Sorafenib DCSXMBR Sorafenib Malignant melanoma (Cell Line: UACC62) [5]
Dasatinib + Sorafenib DCZRRSL Sorafenib Melanoma (Cell Line: MALME-3M) [5]
Dasatinib + Sorafenib DCJ8PZK Sorafenib Mesothelioma (Cell Line: MSTO) [5]
Dasatinib + Sorafenib DCTAHEJ Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Dasatinib + Sorafenib DCSR4NY Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Dasatinib + Sorafenib DCXQRCU Sorafenib Prostate carcinoma (Cell Line: VCAP) [5]
Dasatinib + ER819762 DCKC7YL ER819762 Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Dasatinib + ER819762 DCMV3ZR ER819762 Amelanotic melanoma (Cell Line: M14) [5]
Dasatinib + ER819762 DCFYM8W ER819762 Anaplastic large cell lymphoma (Cell Line: SR) [5]
Dasatinib + ER819762 DCHT0N0 ER819762 Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Dasatinib + ER819762 DC08P16 ER819762 Melanoma (Cell Line: SK-MEL-2) [5]
Dasatinib + PF-562271 DCS1LT2 PF-562271 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Dasatinib + PF-562271 DCEC3HW PF-562271 Diffuse large B cell lymphoma (Cell Line: TMD8) [5]
Dasatinib + Pomalidomide DCKF1EY Pomalidomide Adenocarcinoma (Cell Line: DU-145) [5]
Dasatinib + Pomalidomide DCRESTH Pomalidomide Adenocarcinoma (Cell Line: SW-620) [5]
Dasatinib + Pomalidomide DCJHKGS Pomalidomide Adenocarcinoma (Cell Line: HCC-2998) [5]
Dasatinib + Pomalidomide DC6JVYA Pomalidomide Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Dasatinib + Pomalidomide DC8EHV9 Pomalidomide Melanoma (Cell Line: UACC-257) [5]
Dasatinib + Pomalidomide DCM2MI9 Pomalidomide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Dasatinib + Pomalidomide DC02XXL Pomalidomide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Dasatinib + Vinflunine DCUIZLP Vinflunine Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Dasatinib + Vinflunine DC4M7CD Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Dasatinib + Mercaptopurine DC8BNE2 Mercaptopurine Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Dasatinib + Mercaptopurine DC789MI Mercaptopurine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Dasatinib + Mercaptopurine DCCUKDN Mercaptopurine Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Dasatinib + Mercaptopurine DCTBRSQ Mercaptopurine Lung adenocarcinoma (Cell Line: HOP-62) [5]
Dasatinib + Mercaptopurine DCKEQQR Mercaptopurine Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Dasatinib + Mercaptopurine DC9RI75 Mercaptopurine Prostate carcinoma (Cell Line: PC-3) [5]
Dasatinib + Mepacrine DCUM5RK Mepacrine Adenocarcinoma (Cell Line: HCT-15) [5]
Dasatinib + Mepacrine DCT72W5 Mepacrine Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Dasatinib + Mepacrine DC6UPN5 Mepacrine Amelanotic melanoma (Cell Line: M14) [5]
Dasatinib + Mepacrine DCIFZ70 Mepacrine Anaplastic large cell lymphoma (Cell Line: SR) [5]
Dasatinib + Mepacrine DCUENM9 Mepacrine Astrocytoma (Cell Line: U251) [5]
Dasatinib + Mepacrine DCD4O2E Mepacrine Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Dasatinib + AZD8330 DCEQ5Y2 AZD8330 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Dasatinib + Mefloquine DCKSUPG Mefloquine Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Dasatinib + Mefloquine DCXF0BX Mefloquine Primitive neuroectodermal tumor (Cell Line: TC-32) [5]
Dasatinib + CPG 52364 DCHQTW2 CPG 52364 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Dasatinib + PMID28870136-Compound-43 DCP8NST PMID28870136-Compound-43 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Dasatinib + FORMESTANE DC0JCZQ FORMESTANE Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + FORMESTANE DCJI8FC FORMESTANE Adenocarcinoma (Cell Line: HCC-2998) [5]
Dasatinib + FORMESTANE DC9CE0O FORMESTANE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Dasatinib + FORMESTANE DCMM2IJ FORMESTANE Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Dasatinib + FORMESTANE DCMZ5N8 FORMESTANE Malignant melanoma (Cell Line: LOX IMVI) [5]
Dasatinib + Vorinostat DCB0QV7 Vorinostat Adenocarcinoma (Cell Line: CAOV3) [5]
Dasatinib + Vorinostat DC99OCZ Vorinostat Adenocarcinoma (Cell Line: A427) [5]
Dasatinib + Vorinostat DC9RPUC Vorinostat Adenocarcinoma (Cell Line: NCIH520) [5]
Dasatinib + Vorinostat DC6OMNL Vorinostat Adenocarcinoma (Cell Line: DLD1) [5]
Dasatinib + Vorinostat DC90R6W Vorinostat Amelanotic melanoma (Cell Line: A2058) [5]
Dasatinib + Vorinostat DCFNNXN Vorinostat Germ cell tumour (Cell Line: PA1) [5]
Dasatinib + Vorinostat DCRLERA Vorinostat Malignant melanoma (Cell Line: A375) [5]
Dasatinib + Vorinostat DCL7511 Vorinostat Mesothelioma (Cell Line: MSTO) [5]
Dasatinib + Vorinostat DC435CN Vorinostat Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Dasatinib + Aminolevulinic Acid Hydrochloride DCYSDWO Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: DU-145) [5]
Dasatinib + Aminolevulinic Acid Hydrochloride DCFY9SW Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: A549) [5]
Dasatinib + Aminolevulinic Acid Hydrochloride DCHLBS5 Aminolevulinic Acid Hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Dasatinib + Aminolevulinic Acid Hydrochloride DCWOWJH Aminolevulinic Acid Hydrochloride Anaplastic large cell lymphoma (Cell Line: SR) [5]
Dasatinib + Aminolevulinic Acid Hydrochloride DC0A8Z6 Aminolevulinic Acid Hydrochloride Astrocytoma (Cell Line: U251) [5]
Dasatinib + Aminolevulinic Acid Hydrochloride DCVNBZN Aminolevulinic Acid Hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Dasatinib + Busulfan DCH62LX Busulfan Adenocarcinoma (Cell Line: NCIH23) [5]
Dasatinib + Busulfan DCHDRXI Busulfan Adenocarcinoma (Cell Line: HCT116) [5]
Dasatinib + Busulfan DCQQQKM Busulfan Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Dasatinib + Ibrutinib DC8PXRI Ibrutinib Diffuse large B cell lymphoma (Cell Line: TMD8) [5]
Dasatinib + Lapatinib DCQMI9N Lapatinib Carcinoma (Cell Line: RXF 393) [6]
Dasatinib + Lapatinib DCF80D1 Lapatinib Carcinoma (Cell Line: MCF7) [6]
Dasatinib + RTB101 DCA11XE RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Dasatinib + RTB101 DC3DWU3 RTB101 Breast carcinoma (Cell Line: KPL1) [6]
Dasatinib + RTB101 DCAJCZW RTB101 Breast carcinoma (Cell Line: OCUBM) [6]
Dasatinib + RTB101 DCG0TK4 RTB101 Carcinoma (Cell Line: OV90) [6]
Dasatinib + RTB101 DC3XS8V RTB101 Carcinoma (Cell Line: MDAMB436) [6]
Dasatinib + RTB101 DCZCMLP RTB101 Colon carcinoma (Cell Line: RKO) [6]
Dasatinib + RTB101 DCT7J7O RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + RTB101 DCCHYFS RTB101 Rectal adenocarcinoma (Cell Line: SW837) [6]
Dasatinib + SCH-900776 DCIFJUZ SCH-900776 Breast carcinoma (Cell Line: KPL1) [6]
Dasatinib + SCH-900776 DCJKEC5 SCH-900776 Breast carcinoma (Cell Line: OCUBM) [6]
Dasatinib + SCH-900776 DC7O2QQ SCH-900776 Carcinoma (Cell Line: OV90) [6]
Dasatinib + SCH-900776 DCPLBS2 SCH-900776 Carcinoma (Cell Line: EFM192B) [6]
Dasatinib + SCH-900776 DCCES8B SCH-900776 Carcinoma (Cell Line: MDAMB436) [6]
Dasatinib + SCH-900776 DC18BU6 SCH-900776 Colon adenocarcinoma (Cell Line: LOVO) [6]
Dasatinib + SCH-900776 DCTOVGO SCH-900776 Colon carcinoma (Cell Line: RKO) [6]
Dasatinib + SCH-900776 DCO3ZBC SCH-900776 Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + SCH-900776 DC7VTUM SCH-900776 Rectal adenocarcinoma (Cell Line: SW837) [6]
Dasatinib + Plicamycin DCFF6M7 Plicamycin Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + 10-hydroxycamptothecin DC8AJ6K 10-hydroxycamptothecin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Dasatinib + 10-hydroxycamptothecin DCTLIE8 10-hydroxycamptothecin Breast carcinoma (Cell Line: OCUBM) [6]
Dasatinib + 10-hydroxycamptothecin DC9D8RI 10-hydroxycamptothecin Colon adenocarcinoma (Cell Line: LOVO) [6]
Dasatinib + 10-hydroxycamptothecin DCTA2SC 10-hydroxycamptothecin Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + 10-hydroxycamptothecin DC1RN5U 10-hydroxycamptothecin Rectal adenocarcinoma (Cell Line: SW837) [6]
Dasatinib + Pralatrexate DCX1OHC Pralatrexate Carcinoma (Cell Line: MCF7) [6]
Dasatinib + SNX-2112 DCWPFTL SNX-2112 Breast carcinoma (Cell Line: KPL1) [6]
Dasatinib + SNX-2112 DC9VB4W SNX-2112 Breast carcinoma (Cell Line: OCUBM) [6]
Dasatinib + SNX-2112 DCPRO9Z SNX-2112 Carcinoma (Cell Line: OV90) [6]
Dasatinib + SNX-2112 DCQCDXX SNX-2112 Carcinoma (Cell Line: EFM192B) [6]
Dasatinib + SNX-2112 DCWPX5E SNX-2112 Colon adenocarcinoma (Cell Line: LOVO) [6]
Dasatinib + SNX-2112 DC45XRB SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + SNX-2112 DCDUC2W SNX-2112 Rectal adenocarcinoma (Cell Line: SW837) [6]
Dasatinib + Terameprocol DCX75RP Terameprocol Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Dasatinib + Terameprocol DCGGW8T Terameprocol Colon adenocarcinoma (Cell Line: COLO 205) [6]
Dasatinib + Bendamustine hydrochloride DCEU2GZ Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + Ridaforolimus DCYHA38 Ridaforolimus Breast carcinoma (Cell Line: KPL1) [6]
Dasatinib + Ridaforolimus DCZJH7D Ridaforolimus Breast carcinoma (Cell Line: OCUBM) [6]
Dasatinib + Ridaforolimus DC3OG0W Ridaforolimus Carcinoma (Cell Line: OV90) [6]
Dasatinib + Ridaforolimus DCK9T9B Ridaforolimus Carcinoma (Cell Line: EFM192B) [6]
Dasatinib + Ridaforolimus DCHBIEM Ridaforolimus Carcinoma (Cell Line: MDAMB436) [6]
Dasatinib + Ridaforolimus DCIJZJ6 Ridaforolimus Colon carcinoma (Cell Line: RKO) [6]
Dasatinib + Ridaforolimus DCBWQPK Ridaforolimus Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + Ridaforolimus DCEDLL2 Ridaforolimus Rectal adenocarcinoma (Cell Line: SW837) [6]
Dasatinib + TEM DCZ42HM TEM Colon carcinoma (Cell Line: KM12) [6]
Dasatinib + TEM DCC61KH TEM Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + MK-4827 DC41GQP MK-4827 Breast carcinoma (Cell Line: KPL1) [6]
Dasatinib + MK-4827 DCHTIDL MK-4827 Breast carcinoma (Cell Line: OCUBM) [6]
Dasatinib + MK-4827 DCM8WTD MK-4827 Carcinoma (Cell Line: OV90) [6]
Dasatinib + MK-4827 DCUFPQ9 MK-4827 Carcinoma (Cell Line: EFM192B) [6]
Dasatinib + MK-4827 DCTGVJV MK-4827 Carcinoma (Cell Line: MDAMB436) [6]
Dasatinib + MK-4827 DCRJ9Z6 MK-4827 Colon carcinoma (Cell Line: RKO) [6]
Dasatinib + MK-4827 DCW9IHJ MK-4827 Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + MK-4827 DCPHZAA MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [6]
Dasatinib + Lomustine DCUS8SY Lomustine Breast carcinoma (Cell Line: OCUBM) [6]
Dasatinib + Bortezomib DCZM9PY Bortezomib Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Dasatinib + Valrubicin DCFNP8E Valrubicin Carcinoma (Cell Line: MCF7) [6]
Dasatinib + Valrubicin DC5M2M6 Valrubicin Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + GSK525762 DCNV16U GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Dasatinib + GSK525762 DCOUQTD GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Dasatinib + GSK525762 DCROVZ0 GSK525762 Carcinoma (Cell Line: EFM192B) [6]
Dasatinib + Sorafenib DCLKBFY Sorafenib Breast carcinoma (Cell Line: ZR751) [6]
Dasatinib + Sorafenib DC49JME Sorafenib Breast carcinoma (Cell Line: KPL1) [6]
Dasatinib + Sorafenib DCRJ623 Sorafenib Breast carcinoma (Cell Line: OCUBM) [6]
Dasatinib + Sorafenib DC8O8G8 Sorafenib Carcinoma (Cell Line: OV90) [6]
Dasatinib + Sorafenib DC7F6YQ Sorafenib Carcinoma (Cell Line: EFM192B) [6]
Dasatinib + Sorafenib DC21LDO Sorafenib Carcinoma (Cell Line: MDAMB436) [6]
Dasatinib + Sorafenib DCKS7GZ Sorafenib Colon adenocarcinoma (Cell Line: LOVO) [6]
Dasatinib + Sorafenib DCNT15U Sorafenib Colon carcinoma (Cell Line: RKO) [6]
Dasatinib + Sorafenib DC07SWA Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + ER819762 DCK6O1X ER819762 Carcinoma (Cell Line: MCF7) [6]
Dasatinib + Pomalidomide DCWB1H2 Pomalidomide Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + Vinflunine DCNWV78 Vinflunine Carcinoma (Cell Line: MCF7) [6]
Dasatinib + Mercaptopurine DCM8827 Mercaptopurine Colon adenocarcinoma (Cell Line: COLO 205) [6]
Dasatinib + Mepacrine DCPKIPN Mepacrine Colon carcinoma (Cell Line: KM12) [6]
Dasatinib + PMID28870136-Compound-43 DCFMICY PMID28870136-Compound-43 Colon carcinoma (Cell Line: KM12) [6]
Dasatinib + Vorinostat DCRJVWA Vorinostat Breast carcinoma (Cell Line: KPL1) [6]
Dasatinib + Vorinostat DC9U3P4 Vorinostat Breast carcinoma (Cell Line: OCUBM) [6]
Dasatinib + Vorinostat DC8QL24 Vorinostat Colon carcinoma (Cell Line: RKO) [6]
Dasatinib + Vorinostat DCZ5KDO Vorinostat Invasive ductal carcinoma (Cell Line: T-47D) [6]
Dasatinib + Aminolevulinic Acid Hydrochloride DCBDMIE Aminolevulinic Acid Hydrochloride Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Dexamethasone + Dasatinib DCU4YAP Dexamethasone Breast carcinoma (Cell Line: KPL1) [6]
Dexamethasone + Dasatinib DCHXVN3 Dexamethasone Colon adenocarcinoma (Cell Line: LOVO) [6]
Dexamethasone + Dasatinib DCI84YB Dexamethasone Adenocarcinoma (Cell Line: CAOV3) [7]
Dexamethasone + Dasatinib DCIS814 Dexamethasone Adenocarcinoma (Cell Line: NCIH2122) [7]
Dexamethasone + Dasatinib DCIBUTG Dexamethasone Adenocarcinoma (Cell Line: NCIH520) [7]
Dexamethasone + Dasatinib DCUPBVC Dexamethasone Adenocarcinoma (Cell Line: COLO320DM) [7]
Dexamethasone + Dasatinib DC2DHLD Dexamethasone Adenocarcinoma (Cell Line: SW-620) [7]
Dexamethasone + Dasatinib DCJ7AB9 Dexamethasone Malignant melanoma (Cell Line: HT144) [7]
Dexamethasone + Dasatinib DC6PHP7 Dexamethasone Mesothelioma (Cell Line: MSTO) [7]
Dexamethasone + Dasatinib DCA3K95 Dexamethasone Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Dexrazoxane + Dasatinib DC8OLMY Dexrazoxane Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Dexrazoxane + Dasatinib DC3DY1N Dexrazoxane Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Dexrazoxane + Dasatinib DC8I1B8 Dexrazoxane Anaplastic large cell lymphoma (Cell Line: SR) [5]
Dexrazoxane + Dasatinib DCSPNNK Dexrazoxane Astrocytoma (Cell Line: SNB-19) [5]
Dexrazoxane + Dasatinib DC4E1SJ Dexrazoxane Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Dexrazoxane + Dasatinib DCJ2WJG Dexrazoxane Carcinoma (Cell Line: MCF7) [6]
Dexrazoxane + Dasatinib DCVWBLZ Dexrazoxane Adenocarcinoma (Cell Line: A549) [7]
Dexrazoxane + Dasatinib DCTVI6F Dexrazoxane Adenocarcinoma (Cell Line: HCT116) [7]
Dexrazoxane + Dasatinib DC4PVWK Dexrazoxane Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
DFN-15 + Dasatinib DCIDC3Y DFN-15 Astrocytoma (Cell Line: SNB-19) [5]
DFN-15 + Dasatinib DCV0W93 DFN-15 Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
DFN-15 + Dasatinib DCOBAIV DFN-15 Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
DFN-15 + Dasatinib DCI10GN DFN-15 Glioblastoma (Cell Line: SNB-75) [5]
DFN-15 + Dasatinib DCWEVTB DFN-15 Glioma (Cell Line: SF-268) [5]
DFN-15 + Dasatinib DCXDJHG DFN-15 Plasma cell myeloma (Cell Line: RPMI-8226) [5]
DFN-15 + Dasatinib DC0TJJ3 DFN-15 Renal cell carcinoma (Cell Line: UO-31) [5]
DFN-15 + Dasatinib DC2KM85 DFN-15 Invasive ductal carcinoma (Cell Line: T-47D) [6]
DFN-15 + Dasatinib DCZ11C5 DFN-15 Invasive ductal carcinoma (Cell Line: HS 578T) [6]
DFN-15 + Dasatinib DC1S66Q DFN-15 Adenocarcinoma (Cell Line: OVCAR3) [7]
DFN-15 + Dasatinib DC2XVAB DFN-15 Lung adenocarcinoma (Cell Line: MDA-MB-231) [7]
DFN-15 + Dasatinib DCOK1NW DFN-15 Lung adenocarcinoma (Cell Line: EKVX) [7]
DFN-15 + Dasatinib DCWK2K9 DFN-15 Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Digitoxin + Dasatinib DC34BJ9 Digitoxin Adenocarcinoma (Cell Line: HCC-2998) [5]
Digitoxin + Dasatinib DCF1HQ7 Digitoxin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Docetaxel + Dasatinib DCGL0TV Docetaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Docetaxel + Dasatinib DCC9SI2 Docetaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Docetaxel + Dasatinib DCNOYH3 Docetaxel Astrocytoma (Cell Line: U251) [5]
Docetaxel + Dasatinib DCF61TG Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Docetaxel + Dasatinib DCQ6C5G Docetaxel Glioma (Cell Line: SF-539) [5]
Docetaxel + Dasatinib DC5WK6D Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Docetaxel + Dasatinib DC7XTB5 Docetaxel Carcinoma (Cell Line: RXF 393) [6]
Docetaxel + Dasatinib DCRUVZS Docetaxel Colon carcinoma (Cell Line: KM12) [6]
Docetaxel + Dasatinib DCUSIID Docetaxel Invasive ductal carcinoma (Cell Line: T-47D) [6]
Doxorubicin + Dasatinib DCS9EC4 Doxorubicin Adenocarcinoma (Cell Line: CAOV3) [5]
Doxorubicin + Dasatinib DC57RVZ Doxorubicin Adenocarcinoma (Cell Line: OVCAR3) [5]
Doxorubicin + Dasatinib DCYO57R Doxorubicin Adenocarcinoma (Cell Line: NCIH1650) [5]
Doxorubicin + Dasatinib DC14EJC Doxorubicin Adenocarcinoma (Cell Line: DLD1) [5]
Doxorubicin + Dasatinib DCR7G0R Doxorubicin Adenocarcinoma (Cell Line: HT29) [5]
Doxorubicin + Dasatinib DCKQ760 Doxorubicin Germ cell tumour (Cell Line: PA1) [5]
Doxorubicin + Dasatinib DCGLAOE Doxorubicin Mesothelioma (Cell Line: MSTO) [5]
Doxorubicin + Dasatinib DCTY93C Doxorubicin Non small cell carcinoma (Cell Line: SKMES1) [5]
Doxorubicin + Dasatinib DCD59EM Doxorubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Doxorubicin + Dasatinib DCHAC5B Doxorubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Doxorubicin + Dasatinib DCM7I0W Doxorubicin Breast carcinoma (Cell Line: OCUBM) [6]
Doxorubicin + Dasatinib DCI6EYL Doxorubicin Colon adenocarcinoma (Cell Line: LOVO) [6]
Doxorubicin + Dasatinib DC4LURL Doxorubicin Invasive ductal carcinoma (Cell Line: T-47D) [6]
Doxorubicin + Dasatinib DCU46SH Doxorubicin Rectal adenocarcinoma (Cell Line: SW837) [6]
Epirubicin + Dasatinib DCPOUQX Epirubicin Astrocytoma (Cell Line: U251) [5]
Epirubicin + Dasatinib DCZIXL2 Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Epirubicin + Dasatinib DCTTA88 Epirubicin Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Epirubicin + Dasatinib DC37TWH Epirubicin Colon carcinoma (Cell Line: KM12) [6]
Epirubicin + Dasatinib DCKAVI2 Epirubicin Invasive ductal carcinoma (Cell Line: T-47D) [6]
Epirubicin + Dasatinib DCUBK35 Epirubicin Adenocarcinoma (Cell Line: A549) [7]
Epirubicin + Dasatinib DC5S8Y6 Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Epirubicin + Dasatinib DCTS2JI Epirubicin Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Epirubicin + Dasatinib DC3DE2B Epirubicin Lung adenocarcinoma (Cell Line: MDA-MB-231) [7]
Epirubicin + Dasatinib DC0UUHW Epirubicin Lung adenocarcinoma (Cell Line: HOP-62) [7]
Epirubicin + Dasatinib DCE6A3K Epirubicin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Epirubicin + Dasatinib DCO2MHQ Epirubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Epirubicin + Dasatinib DCH4RLX Epirubicin Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Epirubicin + Dasatinib DCS1CYY Epirubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Epirubicin + Dasatinib DCIGDJ3 Epirubicin Prostate carcinoma (Cell Line: PC-3) [7]
Erlotinib + Dasatinib DCKHMIR Erlotinib Adenocarcinoma (Cell Line: OVCAR3) [5]
Erlotinib + Dasatinib DCXASAS Erlotinib Adenocarcinoma (Cell Line: A427) [5]
Erlotinib + Dasatinib DCOKAIN Erlotinib Adenocarcinoma (Cell Line: NCIH23) [5]
Erlotinib + Dasatinib DCRCUAJ Erlotinib Adenocarcinoma (Cell Line: NCIH520) [5]
Erlotinib + Dasatinib DC4OIWH Erlotinib Adenocarcinoma (Cell Line: DLD1) [5]
Erlotinib + Dasatinib DCW9GXD Erlotinib Adenocarcinoma (Cell Line: HT29) [5]
Erlotinib + Dasatinib DCYM6YE Erlotinib Adenocarcinoma (Cell Line: SW-620) [5]
Erlotinib + Dasatinib DCZK3PI Erlotinib Amelanotic melanoma (Cell Line: A2058) [5]
Erlotinib + Dasatinib DC1DJ4G Erlotinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Erlotinib + Dasatinib DCSSDPU Erlotinib Germ cell tumour (Cell Line: PA1) [5]
Erlotinib + Dasatinib DCS0JUU Erlotinib Malignant melanoma (Cell Line: A375) [5]
Erlotinib + Dasatinib DC1BPHQ Erlotinib Malignant melanoma (Cell Line: RPMI7951) [5]
Erlotinib + Dasatinib DCA3XTU Erlotinib Malignant melanoma (Cell Line: UACC62) [5]
Erlotinib + Dasatinib DCOACYM Erlotinib Non small cell carcinoma (Cell Line: SKMES1) [5]
Erlotinib + Dasatinib DCNXZAK Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Erlotinib + Dasatinib DC64RRG Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Erlotinib + Dasatinib DCYZ7TL Erlotinib Prostate carcinoma (Cell Line: LNCAP) [5]
Erlotinib + Dasatinib DC5XSKM Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Erlotinib + Dasatinib DCPBR00 Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Erlotinib + Dasatinib DCUMG8Y Erlotinib Breast carcinoma (Cell Line: OCUBM) [6]
Erlotinib + Dasatinib DCJYWIX Erlotinib Carcinoma (Cell Line: OV90) [6]
Erlotinib + Dasatinib DCZZATX Erlotinib Carcinoma (Cell Line: EFM192B) [6]
Erlotinib + Dasatinib DCAF0MC Erlotinib Carcinoma (Cell Line: MDAMB436) [6]
Estramustine + Dasatinib DC3LBJD Estramustine Adenocarcinoma (Cell Line: COLO320DM) [5]
Estramustine + Dasatinib DCX2TI9 Estramustine Adenocarcinoma (Cell Line: SW-620) [5]
Estramustine + Dasatinib DC3NAQ0 Estramustine Astrocytoma (Cell Line: U251) [5]
Estramustine + Dasatinib DCL04VR Estramustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Estramustine + Dasatinib DCIA5Y2 Estramustine Breast carcinoma (Cell Line: KPL1) [6]
Estramustine + Dasatinib DCGOVD5 Estramustine Breast carcinoma (Cell Line: OCUBM) [6]
Estramustine + Dasatinib DCL4P5M Estramustine Carcinoma (Cell Line: EFM192B) [6]
Estramustine + Dasatinib DCPNS07 Estramustine Carcinoma (Cell Line: MDAMB436) [6]
Estramustine + Dasatinib DCF83WE Estramustine Colon adenocarcinoma (Cell Line: LOVO) [6]
Estramustine + Dasatinib DCIXN5E Estramustine Invasive ductal carcinoma (Cell Line: T-47D) [6]
Estramustine + Dasatinib DCS1KXW Estramustine Adenocarcinoma (Cell Line: CAOV3) [7]
Estramustine + Dasatinib DCRVBEL Estramustine Adenocarcinoma (Cell Line: OVCAR3) [7]
Estramustine + Dasatinib DCY0R1C Estramustine Adenocarcinoma (Cell Line: A427) [7]
Estramustine + Dasatinib DCM3M68 Estramustine Adenocarcinoma (Cell Line: NCIH23) [7]
Estramustine + Dasatinib DCKGOPS Estramustine Adenocarcinoma (Cell Line: NCIH520) [7]
Estramustine + Dasatinib DCUFG20 Estramustine Amelanotic melanoma (Cell Line: A2058) [7]
Estramustine + Dasatinib DCCXCA5 Estramustine Germ cell tumour (Cell Line: PA1) [7]
Estramustine + Dasatinib DCFPZ5T Estramustine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [7]
Estramustine + Dasatinib DC3FL79 Estramustine Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Estramustine + Dasatinib DCPYYO0 Estramustine Malignant melanoma (Cell Line: A375) [7]
Estramustine + Dasatinib DCZGYAV Estramustine Malignant melanoma (Cell Line: SKMEL30) [7]
Estramustine + Dasatinib DC5NBBO Estramustine Mesothelioma (Cell Line: MSTO) [7]
Estramustine + Dasatinib DCB5DFX Estramustine Non small cell carcinoma (Cell Line: SKMES1) [7]
Estramustine + Dasatinib DCT3GH5 Estramustine Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Estramustine + Dasatinib DCZXKUI Estramustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Estramustine + Dasatinib DC8N67L Estramustine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Estramustine + Dasatinib DCTK4D2 Estramustine Prostate carcinoma (Cell Line: VCAP) [7]
Etoposide + Dasatinib DC7OLL9 Etoposide Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + Dasatinib DCEBIP9 Etoposide Adenocarcinoma (Cell Line: OVCAR3) [5]
Etoposide + Dasatinib DCRC013 Etoposide Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + Dasatinib DCVYUCE Etoposide Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + Dasatinib DCB4BJC Etoposide Adenocarcinoma (Cell Line: DLD1) [5]
Etoposide + Dasatinib DC97VMI Etoposide Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + Dasatinib DCS8SNS Etoposide Germ cell tumour (Cell Line: PA1) [5]
Etoposide + Dasatinib DC40SRU Etoposide Malignant melanoma (Cell Line: A375) [5]
Etoposide + Dasatinib DC8TMBL Etoposide Mesothelioma (Cell Line: MSTO) [5]
Etoposide + Dasatinib DC2E59W Etoposide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + Dasatinib DCMO17I Etoposide Breast carcinoma (Cell Line: KPL1) [6]
Etoposide + Dasatinib DC7G497 Etoposide Breast carcinoma (Cell Line: OCUBM) [6]
Etoposide + Dasatinib DC2JOG1 Etoposide Carcinoma (Cell Line: MDAMB436) [6]
Etoposide + Dasatinib DCUDXNE Etoposide Colon carcinoma (Cell Line: RKO) [6]
Etoposide + Dasatinib DCNV8U9 Etoposide Rectal adenocarcinoma (Cell Line: SW837) [6]
Evacetrapib + Dasatinib DCUX66F Evacetrapib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Fludarabine + Dasatinib DCWCL5B Fludarabine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Fludarabine + Dasatinib DCEP3CN Fludarabine Invasive ductal carcinoma (Cell Line: T-47D) [6]
Fluorouracil + Dasatinib DC3VSIP Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [5]
Fluorouracil + Dasatinib DCADKI9 Fluorouracil Adenocarcinoma (Cell Line: DLD1) [5]
Fluorouracil + Dasatinib DC1PTVD Fluorouracil Adenocarcinoma (Cell Line: HT29) [5]
Fluorouracil + Dasatinib DCMJ4QJ Fluorouracil Adenocarcinoma (Cell Line: SW-620) [5]
Fluorouracil + Dasatinib DCPGDU7 Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Fluorouracil + Dasatinib DCSRGQ8 Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Fluorouracil + Dasatinib DCTGQMW Fluorouracil Breast carcinoma (Cell Line: KPL1) [6]
Fluorouracil + Dasatinib DCFAKLL Fluorouracil Breast carcinoma (Cell Line: OCUBM) [6]
Fluorouracil + Dasatinib DC73FQA Fluorouracil Carcinoma (Cell Line: OV90) [6]
Fluorouracil + Dasatinib DCNJBAF Fluorouracil Carcinoma (Cell Line: EFM192B) [6]
Fluorouracil + Dasatinib DCK2KXI Fluorouracil Carcinoma (Cell Line: MDAMB436) [6]
Fluorouracil + Dasatinib DC74B5F Fluorouracil Colon adenocarcinoma (Cell Line: LOVO) [6]
Fluorouracil + Dasatinib DCCF4DR Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [6]
Fluorouracil + Dasatinib DCS1FGD Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [7]
Fluorouracil + Dasatinib DCR36T2 Fluorouracil Adenocarcinoma (Cell Line: OVCAR3) [7]
Fluorouracil + Dasatinib DCLZP7J Fluorouracil Adenocarcinoma (Cell Line: A427) [7]
Fluorouracil + Dasatinib DC7PK1R Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [7]
Fluorouracil + Dasatinib DC3SSLW Fluorouracil Adenocarcinoma (Cell Line: NCIH520) [7]
Fluorouracil + Dasatinib DCVPOSZ Fluorouracil Amelanotic melanoma (Cell Line: A2058) [7]
Fluorouracil + Dasatinib DCBM1I7 Fluorouracil Germ cell tumour (Cell Line: PA1) [7]
Fluorouracil + Dasatinib DC4HPQT Fluorouracil Malignant melanoma (Cell Line: A375) [7]
Fluorouracil + Dasatinib DCYM085 Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [7]
Fluorouracil + Dasatinib DCJ4DG3 Fluorouracil Mesothelioma (Cell Line: MSTO) [7]
Fluorouracil + Dasatinib DC4CFT1 Fluorouracil Non small cell carcinoma (Cell Line: SKMES1) [7]
Fluorouracil + Dasatinib DCKEGOE Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Fluorouracil + Dasatinib DC59XH6 Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Fluorouracil + Dasatinib DCHOLHX Fluorouracil Prostate carcinoma (Cell Line: LNCAP) [7]
Fluorouracil + Dasatinib DC36HKG Fluorouracil Prostate carcinoma (Cell Line: VCAP) [7]
Gefitinib + Dasatinib DCIFGH4 Gefitinib Adenocarcinoma (Cell Line: DU-145) [5]
Gefitinib + Dasatinib DCNE3EI Gefitinib Adenocarcinoma (Cell Line: OVCAR3) [5]
Gefitinib + Dasatinib DC18K0Q Gefitinib Adenocarcinoma (Cell Line: A549) [5]
Gefitinib + Dasatinib DCS2DVG Gefitinib Adenocarcinoma (Cell Line: HCT-15) [5]
Gefitinib + Dasatinib DCR2GD6 Gefitinib Adenocarcinoma (Cell Line: HT29) [5]
Gefitinib + Dasatinib DCZD3G4 Gefitinib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Gefitinib + Dasatinib DC17YF1 Gefitinib Glioblastoma (Cell Line: SNB-75) [5]
Gefitinib + Dasatinib DCP1MR2 Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Gefitinib + Dasatinib DC4YOZ1 Gefitinib Lung adenocarcinoma (Cell Line: EKVX) [5]
Gefitinib + Dasatinib DC7RZFZ Gefitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Gefitinib + Dasatinib DCTVMB0 Gefitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Gefitinib + Dasatinib DCD5HNV Gefitinib Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Gefitinib + Dasatinib DCLCIF6 Gefitinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Gefitinib + Dasatinib DC3Q4WL Gefitinib Prostate carcinoma (Cell Line: PC-3) [5]
Gefitinib + Dasatinib DCM7NBN Gefitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Gemcitabine + Dasatinib DCHQIT0 Gemcitabine Adenocarcinoma (Cell Line: A427) [5]
Gemcitabine + Dasatinib DCR050M Gemcitabine Adenocarcinoma (Cell Line: NCIH520) [5]
Gemcitabine + Dasatinib DC2FE0G Gemcitabine Adenocarcinoma (Cell Line: DLD1) [5]
Gemcitabine + Dasatinib DCNUBF5 Gemcitabine Adenocarcinoma (Cell Line: HT29) [5]
Gemcitabine + Dasatinib DCS0YL8 Gemcitabine Germ cell tumour (Cell Line: PA1) [5]
Gemcitabine + Dasatinib DCERVFT Gemcitabine Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Gemcitabine + Dasatinib DCEG5PH Gemcitabine Malignant melanoma (Cell Line: A375) [5]
Gemcitabine + Dasatinib DCXI49M Gemcitabine Mesothelioma (Cell Line: MSTO) [5]
Gemcitabine + Dasatinib DCBC4H2 Gemcitabine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Gemcitabine + Dasatinib DC398ED Gemcitabine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Gemcitabine + Dasatinib DC85HEO Gemcitabine Breast carcinoma (Cell Line: KPL1) [6]
Gemcitabine + Dasatinib DC8CLAK Gemcitabine Breast carcinoma (Cell Line: OCUBM) [6]
Gemcitabine + Dasatinib DCUM3F2 Gemcitabine Carcinoma (Cell Line: MDAMB436) [6]
Gemcitabine + Dasatinib DCHTSP4 Gemcitabine Colon carcinoma (Cell Line: RKO) [6]
Hepzato + Dasatinib DC0IAVX Hepzato Chronic myelogenous leukemia (Cell Line: K-562) [5]
Hepzato + Dasatinib DCPD15T Hepzato Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Idarubicin + Dasatinib DCM41TX Idarubicin Adenocarcinoma (Cell Line: COLO320DM) [5]
Idarubicin + Dasatinib DCK70Y3 Idarubicin Adenocarcinoma (Cell Line: SW-620) [5]
Idarubicin + Dasatinib DCGPYKQ Idarubicin Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Idarubicin + Dasatinib DCS9P4X Idarubicin Adenocarcinoma (Cell Line: A427) [7]
Idarubicin + Dasatinib DC59XVX Idarubicin Amelanotic melanoma (Cell Line: A2058) [7]
Idarubicin + Dasatinib DCQCDK9 Idarubicin Germ cell tumour (Cell Line: PA1) [7]
Idarubicin + Dasatinib DC3PT24 Idarubicin Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Idarubicin + Dasatinib DCCRZI5 Idarubicin Malignant melanoma (Cell Line: RPMI7951) [7]
Idarubicin + Dasatinib DCCYE6G Idarubicin Mesothelioma (Cell Line: MSTO) [7]
Idarubicin + Dasatinib DC0GWGG Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Imatinib + Dasatinib DC0LHK2 Imatinib Adenocarcinoma (Cell Line: NCIH23) [5]
Imatinib + Dasatinib DC2C06F Imatinib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Imatinib + Dasatinib DC7CO1D Imatinib Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Imatinib + Dasatinib DCUYI7M Imatinib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Imatinib + Dasatinib DCMG8HW Imatinib Glioma (Cell Line: SF-539) [5]
Imatinib + Dasatinib DCF3DYK Imatinib Glioma (Cell Line: SF-268) [5]
Imatinib + Dasatinib DCCQZ9Z Imatinib Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Imatinib + Dasatinib DCOYCNT Imatinib Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Indazole derivative 5 + Dasatinib DCA1VVG Indazole derivative 5 Adenocarcinoma (Cell Line: HT29) [5]
Indazole derivative 5 + Dasatinib DCT9XEW Indazole derivative 5 Astrocytoma (Cell Line: SNB-19) [5]
Indazole derivative 5 + Dasatinib DCUWP9H Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [5]
Indazole derivative 5 + Dasatinib DCTP4CI Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: A498) [5]
Indazole derivative 5 + Dasatinib DCAQR7K Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Indazole derivative 5 + Dasatinib DCF0UQD Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Indazole derivative 5 + Dasatinib DCQO3YR Indazole derivative 5 Adenocarcinoma (Cell Line: A549) [7]
Indazole derivative 5 + Dasatinib DC89GDM Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Indazole derivative 5 + Dasatinib DCW8KR7 Indazole derivative 5 Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Indazole derivative 5 + Dasatinib DCS4O5F Indazole derivative 5 Lung adenocarcinoma (Cell Line: HOP-62) [7]
Indazole derivative 5 + Dasatinib DCGGPNC Indazole derivative 5 Lung adenocarcinoma (Cell Line: NCI-H522) [7]
Indazole derivative 5 + Dasatinib DC0PNZS Indazole derivative 5 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Indazole derivative 5 + Dasatinib DCD7Y8V Indazole derivative 5 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Indazole derivative 5 + Dasatinib DCEI01Y Indazole derivative 5 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Indazole derivative 5 + Dasatinib DCNYCK2 Indazole derivative 5 Prostate carcinoma (Cell Line: PC-3) [7]
JNK-IN-8 + Dasatinib DC2299O JNK-IN-8 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
JNK-IN-8 + Dasatinib DCU02UX JNK-IN-8 Anaplastic large cell lymphoma (Cell Line: SR) [5]
JNK-IN-8 + Dasatinib DCPBTVR JNK-IN-8 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
JNK-IN-8 + Dasatinib DCGMPEN JNK-IN-8 Papillary renal cell carcinoma (Cell Line: ACHN) [5]
JNK-IN-8 + Dasatinib DCZFMGV JNK-IN-8 Renal cell carcinoma (Cell Line: UO-31) [5]
JNK-IN-8 + Dasatinib DCU3682 JNK-IN-8 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [7]
Lapatinib + Dasatinib DCRL7YN Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Lapatinib + Dasatinib DCZE45W Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Lapatinib + Dasatinib DCDBPDI Lapatinib Breast carcinoma (Cell Line: KPL1) [6]
Lapatinib + Dasatinib DC20MCK Lapatinib Breast carcinoma (Cell Line: OCUBM) [6]
Lapatinib + Dasatinib DC5ZUNQ Lapatinib Carcinoma (Cell Line: OV90) [6]
Lapatinib + Dasatinib DC3HX6E Lapatinib Carcinoma (Cell Line: EFM192B) [6]
Lapatinib + Dasatinib DCQW0V2 Lapatinib Colon carcinoma (Cell Line: RKO) [6]
Lapatinib + Dasatinib DCIXM1A Lapatinib Rectal adenocarcinoma (Cell Line: SW837) [6]
Lapatinib + Dasatinib DCSKTZM Lapatinib Adenocarcinoma (Cell Line: CAOV3) [7]
Lapatinib + Dasatinib DCGGLRL Lapatinib Adenocarcinoma (Cell Line: A427) [7]
Lapatinib + Dasatinib DC7D1H4 Lapatinib Adenocarcinoma (Cell Line: NCIH520) [7]
Lapatinib + Dasatinib DCD4Q38 Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [7]
Lapatinib + Dasatinib DCFHMFN Lapatinib Adenocarcinoma (Cell Line: DLD1) [7]
Lapatinib + Dasatinib DCACNCL Lapatinib Adenocarcinoma (Cell Line: HT29) [7]
Lapatinib + Dasatinib DCA4JT6 Lapatinib Adenocarcinoma (Cell Line: SW-620) [7]
Lapatinib + Dasatinib DCJ75EP Lapatinib Amelanotic melanoma (Cell Line: A2058) [7]
Lapatinib + Dasatinib DCW9ZKO Lapatinib Germ cell tumour (Cell Line: PA1) [7]
Lapatinib + Dasatinib DCW4F94 Lapatinib Malignant melanoma (Cell Line: RPMI7951) [7]
Lapatinib + Dasatinib DCFW8OO Lapatinib Malignant melanoma (Cell Line: SKMEL30) [7]
Lapatinib + Dasatinib DCZES1H Lapatinib Malignant melanoma (Cell Line: UACC62) [7]
Lapatinib + Dasatinib DCSV0CI Lapatinib Mesothelioma (Cell Line: MSTO) [7]
Lapatinib + Dasatinib DC5S8N4 Lapatinib Non small cell carcinoma (Cell Line: SKMES1) [7]
Lapatinib + Dasatinib DC2S6AT Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Lapatinib + Dasatinib DCDCM19 Lapatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Lapatinib + Dasatinib DCXYWK3 Lapatinib Prostate carcinoma (Cell Line: LNCAP) [7]
Lapatinib + Dasatinib DCTIN0Y Lapatinib Prostate carcinoma (Cell Line: VCAP) [7]
Lenalidomide + Dasatinib DCIHZYK Lenalidomide Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Lenalidomide + Dasatinib DC57Z1L Lenalidomide Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Lenalidomide + Dasatinib DC20WT7 Lenalidomide Adenocarcinoma (Cell Line: HCC-2998) [7]
Letrozole + Dasatinib DC1RMIV Letrozole Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Letrozole + Dasatinib DCP9NFL Letrozole Colon adenocarcinoma (Cell Line: COLO 205) [6]
LIAROZOLE + Dasatinib DCEPBOO LIAROZOLE Glioma (Cell Line: SF-268) [5]
LIAROZOLE + Dasatinib DC3Y3MT LIAROZOLE Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Mechlorethamine + Dasatinib DCI6ADI Mechlorethamine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Mechlorethamine + Dasatinib DCWV2WW Mechlorethamine Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Mechlorethamine + Dasatinib DC6JLZH Mechlorethamine Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Mechlorethamine + Dasatinib DCKM10J Mechlorethamine Colon adenocarcinoma (Cell Line: COLO 205) [6]
Mechlorethamine + Dasatinib DCSG695 Mechlorethamine Adenocarcinoma (Cell Line: HCC-2998) [7]
Metformin + Dasatinib DCT27YV Metformin Adenocarcinoma (Cell Line: A427) [5]
Metformin + Dasatinib DC37316 Metformin Adenocarcinoma (Cell Line: NCIH520) [5]
Metformin + Dasatinib DCIJ7VA Metformin Adenocarcinoma (Cell Line: COLO320DM) [5]
Metformin + Dasatinib DCIEWQP Metformin Adenocarcinoma (Cell Line: HT29) [5]
Metformin + Dasatinib DCJ0PGD Metformin Adenocarcinoma (Cell Line: SW-620) [5]
Metformin + Dasatinib DCJ5T1P Metformin Malignant melanoma (Cell Line: SKMEL30) [5]
Metformin + Dasatinib DCFEFV6 Metformin Mesothelioma (Cell Line: MSTO) [5]
Metformin + Dasatinib DC2N4QX Metformin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Metformin + Dasatinib DCJJNHX Metformin Prostate carcinoma (Cell Line: VCAP) [5]
Metformin + Dasatinib DCTKKFG Metformin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Metformin + Dasatinib DC8GAY2 Metformin Carcinoma (Cell Line: EFM192B) [6]
Metformin + Dasatinib DC6FWMW Metformin Carcinoma (Cell Line: MDAMB436) [6]
Methotrexate + Dasatinib DC4L6AG Methotrexate Adenocarcinoma (Cell Line: NCIH23) [5]
Methotrexate + Dasatinib DCXU18P Methotrexate Germ cell tumour (Cell Line: PA1) [5]
Methotrexate + Dasatinib DCKNNR0 Methotrexate Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Methotrexate + Dasatinib DC0NDDZ Methotrexate Prostate carcinoma (Cell Line: VCAP) [5]
Mitomycin + Dasatinib DCCIMFE Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Mitomycin + Dasatinib DCUS90H Mitomycin Breast carcinoma (Cell Line: KPL1) [6]
Mitomycin + Dasatinib DCML89V Mitomycin Breast carcinoma (Cell Line: OCUBM) [6]
Mitomycin + Dasatinib DCOZDAB Mitomycin Colon adenocarcinoma (Cell Line: LOVO) [6]
Mitomycin + Dasatinib DCI8ULC Mitomycin Colon carcinoma (Cell Line: RKO) [6]
Mitomycin + Dasatinib DC6C71W Mitomycin Invasive ductal carcinoma (Cell Line: T-47D) [6]
Mitomycin + Dasatinib DC6CG1X Mitomycin Rectal adenocarcinoma (Cell Line: SW837) [6]
Mitomycin + Dasatinib DC9MFFE Mitomycin Adenocarcinoma (Cell Line: CAOV3) [7]
Mitomycin + Dasatinib DCLK8KQ Mitomycin Adenocarcinoma (Cell Line: OVCAR3) [7]
Mitomycin + Dasatinib DCG3NVY Mitomycin Adenocarcinoma (Cell Line: A427) [7]
Mitomycin + Dasatinib DC6Y3U4 Mitomycin Adenocarcinoma (Cell Line: NCIH1650) [7]
Mitomycin + Dasatinib DCUOYL9 Mitomycin Adenocarcinoma (Cell Line: NCIH23) [7]
Mitomycin + Dasatinib DCIDAL9 Mitomycin Adenocarcinoma (Cell Line: DLD1) [7]
Mitomycin + Dasatinib DCE02N1 Mitomycin Adenocarcinoma (Cell Line: HT29) [7]
Mitomycin + Dasatinib DCZO91F Mitomycin Adenocarcinoma (Cell Line: SW-620) [7]
Mitomycin + Dasatinib DCBIVA6 Mitomycin Amelanotic melanoma (Cell Line: A2058) [7]
Mitomycin + Dasatinib DCAGHXL Mitomycin Germ cell tumour (Cell Line: PA1) [7]
Mitomycin + Dasatinib DCOTG29 Mitomycin Malignant melanoma (Cell Line: A375) [7]
Mitomycin + Dasatinib DCIHWXA Mitomycin Malignant melanoma (Cell Line: RPMI7951) [7]
Mitomycin + Dasatinib DCCH8F7 Mitomycin Mesothelioma (Cell Line: MSTO) [7]
Mitomycin + Dasatinib DCYA9Q9 Mitomycin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
MK-1775 + Dasatinib DCBK4TC MK-1775 Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-1775 + Dasatinib DC2BAIJ MK-1775 Adenocarcinoma (Cell Line: A427) [5]
MK-1775 + Dasatinib DCPCIOP MK-1775 Adenocarcinoma (Cell Line: NCIH520) [5]
MK-1775 + Dasatinib DCI9ORQ MK-1775 Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-1775 + Dasatinib DC4XX4A MK-1775 Adenocarcinoma (Cell Line: DLD1) [5]
MK-1775 + Dasatinib DCW3TM8 MK-1775 Adenocarcinoma (Cell Line: HT29) [5]
MK-1775 + Dasatinib DCS4H28 MK-1775 Adenocarcinoma (Cell Line: SW-620) [5]
MK-1775 + Dasatinib DCS1RPI MK-1775 Germ cell tumour (Cell Line: PA1) [5]
MK-1775 + Dasatinib DCTWNDY MK-1775 Malignant melanoma (Cell Line: A375) [5]
MK-1775 + Dasatinib DCLS3W5 MK-1775 Malignant melanoma (Cell Line: RPMI7951) [5]
MK-1775 + Dasatinib DCWU01F MK-1775 Mesothelioma (Cell Line: MSTO) [5]
MK-1775 + Dasatinib DCN716R MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-1775 + Dasatinib DCV6ZA0 MK-1775 Breast carcinoma (Cell Line: ZR751) [6]
MK-1775 + Dasatinib DCBAEKF MK-1775 Breast carcinoma (Cell Line: KPL1) [6]
MK-1775 + Dasatinib DC4HIXA MK-1775 Breast carcinoma (Cell Line: OCUBM) [6]
MK-1775 + Dasatinib DCPQITR MK-1775 Colon carcinoma (Cell Line: RKO) [6]
MK-2206 + Dasatinib DCAWFVY MK-2206 Adenocarcinoma (Cell Line: A427) [5]
MK-2206 + Dasatinib DCYJM5A MK-2206 Adenocarcinoma (Cell Line: NCIH1650) [5]
MK-2206 + Dasatinib DC5FLF7 MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [5]
MK-2206 + Dasatinib DC928TJ MK-2206 Adenocarcinoma (Cell Line: NCIH23) [5]
MK-2206 + Dasatinib DCTO8H9 MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-2206 + Dasatinib DCHVEXL MK-2206 Adenocarcinoma (Cell Line: DLD1) [5]
MK-2206 + Dasatinib DCG125Y MK-2206 Adenocarcinoma (Cell Line: HCT116) [5]
MK-2206 + Dasatinib DCPE0CP MK-2206 Adenocarcinoma (Cell Line: HT29) [5]
MK-2206 + Dasatinib DCQ0DTR MK-2206 Adenocarcinoma (Cell Line: SW-620) [5]
MK-2206 + Dasatinib DCBIB4Q MK-2206 Amelanotic melanoma (Cell Line: A2058) [5]
MK-2206 + Dasatinib DCTJWNV MK-2206 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
MK-2206 + Dasatinib DCOAIIM MK-2206 Germ cell tumour (Cell Line: PA1) [5]
MK-2206 + Dasatinib DC0TNZ5 MK-2206 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
MK-2206 + Dasatinib DCTTM22 MK-2206 Malignant melanoma (Cell Line: A375) [5]
MK-2206 + Dasatinib DC16HZJ MK-2206 Malignant melanoma (Cell Line: HT144) [5]
MK-2206 + Dasatinib DC4X84Z MK-2206 Malignant melanoma (Cell Line: SKMEL30) [5]
MK-2206 + Dasatinib DCSZR43 MK-2206 Malignant melanoma (Cell Line: UACC62) [5]
MK-2206 + Dasatinib DCM6GNR MK-2206 Mesothelioma (Cell Line: MSTO) [5]
MK-2206 + Dasatinib DCOULUV MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [5]
MK-2206 + Dasatinib DC9ZKKF MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-2206 + Dasatinib DCI3MDE MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-2206 + Dasatinib DC9JINO MK-2206 Prostate carcinoma (Cell Line: LNCAP) [5]
MK-2206 + Dasatinib DCSZQAV MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
MK-2206 + Dasatinib DCIJONC MK-2206 Breast carcinoma (Cell Line: KPL1) [6]
MK-2206 + Dasatinib DC4A2UK MK-2206 Breast carcinoma (Cell Line: OCUBM) [6]
MK-2206 + Dasatinib DC23X31 MK-2206 Carcinoma (Cell Line: OV90) [6]
MK-2206 + Dasatinib DCF05UM MK-2206 Carcinoma (Cell Line: EFM192B) [6]
MK-2206 + Dasatinib DCWYYIL MK-2206 Carcinoma (Cell Line: MDAMB436) [6]
MK-2206 + Dasatinib DCKGU6P MK-2206 Colon carcinoma (Cell Line: RKO) [6]
MK-2206 + Dasatinib DCEZ0SU MK-2206 Invasive ductal carcinoma (Cell Line: T-47D) [6]
MK-2206 + Dasatinib DCS772R MK-2206 Rectal adenocarcinoma (Cell Line: SW837) [6]
MK-5108 + Dasatinib DCLNW2S MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
MK-5108 + Dasatinib DC8VII9 MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
MK-5108 + Dasatinib DCS08RY MK-5108 Breast carcinoma (Cell Line: OCUBM) [6]
MK-5108 + Dasatinib DCIEB0V MK-5108 Carcinoma (Cell Line: MDAMB436) [6]
MK-5108 + Dasatinib DCVDAU3 MK-5108 Colon adenocarcinoma (Cell Line: LOVO) [6]
MK-5108 + Dasatinib DCUVADY MK-5108 Colon carcinoma (Cell Line: RKO) [6]
MK-5108 + Dasatinib DCJHT1N MK-5108 Adenocarcinoma (Cell Line: CAOV3) [7]
MK-5108 + Dasatinib DCDAUVE MK-5108 Adenocarcinoma (Cell Line: A427) [7]
MK-5108 + Dasatinib DCHTDLJ MK-5108 Adenocarcinoma (Cell Line: NCIH520) [7]
MK-5108 + Dasatinib DCTVEUS MK-5108 Adenocarcinoma (Cell Line: DLD1) [7]
MK-5108 + Dasatinib DCCS3KO MK-5108 Adenocarcinoma (Cell Line: HT29) [7]
MK-5108 + Dasatinib DCEBA58 MK-5108 Adenocarcinoma (Cell Line: SW-620) [7]
MK-5108 + Dasatinib DCRYI17 MK-5108 Amelanotic melanoma (Cell Line: A2058) [7]
MK-5108 + Dasatinib DCYYQPZ MK-5108 Germ cell tumour (Cell Line: PA1) [7]
MK-5108 + Dasatinib DCI223R MK-5108 Malignant melanoma (Cell Line: A375) [7]
MK-5108 + Dasatinib DCBTCOQ MK-5108 Malignant melanoma (Cell Line: UACC62) [7]
MK-5108 + Dasatinib DC9DXN6 MK-5108 Mesothelioma (Cell Line: MSTO) [7]
MK-5108 + Dasatinib DCVGLKA MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Nilotinib + Dasatinib DC0A0XW Nilotinib Colon adenocarcinoma (Cell Line: COLO 205) [6]
PD-0325901 + Dasatinib DCC9DG6 PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
PD-0325901 + Dasatinib DCFZMUL PD-0325901 Breast carcinoma (Cell Line: KPL1) [6]
PD-0325901 + Dasatinib DCO7WUY PD-0325901 Breast carcinoma (Cell Line: OCUBM) [6]
PD-0325901 + Dasatinib DCXMAB7 PD-0325901 Carcinoma (Cell Line: OV90) [6]
PD-0325901 + Dasatinib DCE34VG PD-0325901 Carcinoma (Cell Line: EFM192B) [6]
PD-0325901 + Dasatinib DCXLPF4 PD-0325901 Carcinoma (Cell Line: MDAMB436) [6]
PD-0325901 + Dasatinib DCDCPW3 PD-0325901 Colon carcinoma (Cell Line: RKO) [6]
PD-0325901 + Dasatinib DCR02ZL PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [6]
PD-0325901 + Dasatinib DC34X96 PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [6]
PD-0325901 + Dasatinib DCY0Y4T PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [7]
PD-0325901 + Dasatinib DCCGBVS PD-0325901 Adenocarcinoma (Cell Line: OVCAR3) [7]
PD-0325901 + Dasatinib DCUY5X6 PD-0325901 Adenocarcinoma (Cell Line: A427) [7]
PD-0325901 + Dasatinib DCR365O PD-0325901 Adenocarcinoma (Cell Line: NCIH1650) [7]
PD-0325901 + Dasatinib DCN6L5Z PD-0325901 Adenocarcinoma (Cell Line: NCIH23) [7]
PD-0325901 + Dasatinib DCZDUH8 PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [7]
PD-0325901 + Dasatinib DCDLIUN PD-0325901 Adenocarcinoma (Cell Line: DLD1) [7]
PD-0325901 + Dasatinib DC2KEXR PD-0325901 Adenocarcinoma (Cell Line: HT29) [7]
PD-0325901 + Dasatinib DCPI7BV PD-0325901 Adenocarcinoma (Cell Line: SW-620) [7]
PD-0325901 + Dasatinib DCYNB3X PD-0325901 Amelanotic melanoma (Cell Line: A2058) [7]
PD-0325901 + Dasatinib DCDLC9Z PD-0325901 Germ cell tumour (Cell Line: PA1) [7]
PD-0325901 + Dasatinib DCFZES4 PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [7]
PD-0325901 + Dasatinib DCHD0AB PD-0325901 Malignant melanoma (Cell Line: A375) [7]
PD-0325901 + Dasatinib DCXU44K PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [7]
PD-0325901 + Dasatinib DCMODXC PD-0325901 Malignant melanoma (Cell Line: UACC62) [7]
PD-0325901 + Dasatinib DC9UHQM PD-0325901 Mesothelioma (Cell Line: MSTO) [7]
PD-0325901 + Dasatinib DCQPPGN PD-0325901 Non small cell carcinoma (Cell Line: SKMES1) [7]
PD-0325901 + Dasatinib DC0R5QP PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
PD-0325901 + Dasatinib DC4UCVP PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
PD-0325901 + Dasatinib DC54J98 PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [7]
PD-0325901 + Dasatinib DC9UBBI PD-0325901 Prostate carcinoma (Cell Line: VCAP) [7]
Picoplatin + Dasatinib DCZ8EV2 Picoplatin Anaplastic large cell lymphoma (Cell Line: SR) [5]
Picoplatin + Dasatinib DCX2HND Picoplatin Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
PMID28460551-Compound-2 + Dasatinib DCA3681 PMID28460551-Compound-2 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
PMID28460551-Compound-2 + Dasatinib DCDJKMT PMID28460551-Compound-2 Chronic myelogenous leukemia (Cell Line: K-562) [5]
PMID28460551-Compound-2 + Dasatinib DCVK7WW PMID28460551-Compound-2 Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
PMID28460551-Compound-2 + Dasatinib DCZRIPZ PMID28460551-Compound-2 Breast carcinoma (Cell Line: KPL1) [6]
PMID28460551-Compound-2 + Dasatinib DC3I1JT PMID28460551-Compound-2 Breast carcinoma (Cell Line: OCUBM) [6]
PMID28460551-Compound-2 + Dasatinib DCIOFBP PMID28460551-Compound-2 Carcinoma (Cell Line: OV90) [6]
PMID28460551-Compound-2 + Dasatinib DCY2NJ2 PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [6]
PMID28460551-Compound-2 + Dasatinib DCM3Y64 PMID28460551-Compound-2 Colon carcinoma (Cell Line: RKO) [6]
PMID28460551-Compound-2 + Dasatinib DCP1JK7 PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [6]
PMID28460551-Compound-2 + Dasatinib DCGP8V9 PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [6]
PMID28460551-Compound-2 + Dasatinib DCVCSZX PMID28460551-Compound-2 Adenocarcinoma (Cell Line: OVCAR3) [7]
PMID28460551-Compound-2 + Dasatinib DCOQ8ZV PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH1650) [7]
PMID28460551-Compound-2 + Dasatinib DCAHMGO PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [7]
PMID28460551-Compound-2 + Dasatinib DCJ1IOV PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCT116) [7]
PMID28460551-Compound-2 + Dasatinib DCWM64F PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCT-15) [7]
PMID28460551-Compound-2 + Dasatinib DCDKI86 PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [7]
PMID28460551-Compound-2 + Dasatinib DCGMDEW PMID28460551-Compound-2 Germ cell tumour (Cell Line: PA1) [7]
PMID28460551-Compound-2 + Dasatinib DC42CDK PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: HOP-62) [7]
PMID28460551-Compound-2 + Dasatinib DCWJZ4D PMID28460551-Compound-2 Malignant melanoma (Cell Line: UACC62) [7]
PMID28460551-Compound-2 + Dasatinib DCVBFJF PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [7]
PMID28460551-Compound-2 + Dasatinib DC7AIQV PMID28460551-Compound-2 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
PMID28460551-Compound-2 + Dasatinib DCJBHD8 PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [7]
PMID28460551-Compound-2 + Dasatinib DCNLMM8 PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
PMID28460551-Compound-2 + Dasatinib DC5PRQK PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [7]
Raloxifene + Dasatinib DC6L404 Raloxifene Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Raloxifene + Dasatinib DCCP3EJ Raloxifene Carcinoma (Cell Line: MCF7) [6]
Raloxifene + Dasatinib DC4Q2JL Raloxifene Colon carcinoma (Cell Line: KM12) [6]
Raloxifene + Dasatinib DCM91KE Raloxifene Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Raloxifene + Dasatinib DCMR2M2 Raloxifene Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Ridaforolimus + Dasatinib DCOE2EY Ridaforolimus Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Ruxolitinib + Dasatinib DCUWJ67 Ruxolitinib Astrocytoma (Cell Line: U251) [5]
Ruxolitinib + Dasatinib DCMIKSM Ruxolitinib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Ruxolitinib + Dasatinib DC9EST0 Ruxolitinib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Ruxolitinib + Dasatinib DCU5R2F Ruxolitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Ruxolitinib + Dasatinib DCJLVNL Ruxolitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Ruxolitinib + Dasatinib DC2S7YS Ruxolitinib Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Ruxolitinib + Dasatinib DCOHWJT Ruxolitinib Carcinoma (Cell Line: RXF 393) [6]
Ruxolitinib + Dasatinib DCNEOKG Ruxolitinib Colon carcinoma (Cell Line: KM12) [6]
Ruxolitinib + Dasatinib DC1RG5H Ruxolitinib Invasive ductal carcinoma (Cell Line: T-47D) [6]
Ruxolitinib + Dasatinib DCOAK3V Ruxolitinib Adenocarcinoma (Cell Line: DU-145) [7]
Ruxolitinib + Dasatinib DCNWWXK Ruxolitinib Adenocarcinoma (Cell Line: A549) [7]
Ruxolitinib + Dasatinib DCAJIC7 Ruxolitinib Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Ruxolitinib + Dasatinib DCPE7WK Ruxolitinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [7]
Ruxolitinib + Dasatinib DCMLXNI Ruxolitinib Lung adenocarcinoma (Cell Line: HOP-62) [7]
Ruxolitinib + Dasatinib DCT21D2 Ruxolitinib Lung adenocarcinoma (Cell Line: EKVX) [7]
Ruxolitinib + Dasatinib DC3NWWE Ruxolitinib Lung adenocarcinoma (Cell Line: NCI-H522) [7]
Ruxolitinib + Dasatinib DC35A7W Ruxolitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Ruxolitinib + Dasatinib DCHDQL0 Ruxolitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Ruxolitinib + Dasatinib DCW2O98 Ruxolitinib Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Ruxolitinib + Dasatinib DCTLSSZ Ruxolitinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Ruxolitinib + Dasatinib DC85G4X Ruxolitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Ruxolitinib + Dasatinib DC1FD43 Ruxolitinib Prostate carcinoma (Cell Line: PC-3) [7]
SCH 727965 + Dasatinib DCJC7I1 SCH 727965 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
SCH 727965 + Dasatinib DCWNMXN SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
SCH 727965 + Dasatinib DCTJGVG SCH 727965 Breast carcinoma (Cell Line: KPL1) [6]
SCH 727965 + Dasatinib DC8OJYT SCH 727965 Breast carcinoma (Cell Line: OCUBM) [6]
SCH 727965 + Dasatinib DCX1IW7 SCH 727965 Carcinoma (Cell Line: EFM192B) [6]
SCH 727965 + Dasatinib DC4PD8L SCH 727965 Carcinoma (Cell Line: MDAMB436) [6]
SCH 727965 + Dasatinib DCIUMCB SCH 727965 Colon adenocarcinoma (Cell Line: LOVO) [6]
SCH 727965 + Dasatinib DCK6RS5 SCH 727965 Colon carcinoma (Cell Line: RKO) [6]
SCH 727965 + Dasatinib DC69RU9 SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [6]
SCH 727965 + Dasatinib DCO26VC SCH 727965 Rectal adenocarcinoma (Cell Line: SW837) [6]
SCH 727965 + Dasatinib DCIMAN2 SCH 727965 Adenocarcinoma (Cell Line: OVCAR3) [7]
SCH 727965 + Dasatinib DCO32AL SCH 727965 Adenocarcinoma (Cell Line: A427) [7]
SCH 727965 + Dasatinib DCA99WV SCH 727965 Adenocarcinoma (Cell Line: NCIH1650) [7]
SCH 727965 + Dasatinib DCFWLRV SCH 727965 Adenocarcinoma (Cell Line: NCIH2122) [7]
SCH 727965 + Dasatinib DC8HPTY SCH 727965 Adenocarcinoma (Cell Line: NCIH23) [7]
SCH 727965 + Dasatinib DC34TGX SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [7]
SCH 727965 + Dasatinib DC4W22K SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [7]
SCH 727965 + Dasatinib DCBUGNW SCH 727965 Adenocarcinoma (Cell Line: DLD1) [7]
SCH 727965 + Dasatinib DC8RO0I SCH 727965 Adenocarcinoma (Cell Line: HCT116) [7]
SCH 727965 + Dasatinib DCDD10G SCH 727965 Adenocarcinoma (Cell Line: HT29) [7]
SCH 727965 + Dasatinib DCESF18 SCH 727965 Adenocarcinoma (Cell Line: SW-620) [7]
SCH 727965 + Dasatinib DCT8Q1V SCH 727965 Amelanotic melanoma (Cell Line: A2058) [7]
SCH 727965 + Dasatinib DCG06CM SCH 727965 Germ cell tumour (Cell Line: PA1) [7]
SCH 727965 + Dasatinib DC92V6B SCH 727965 Large cell lung carcinoma (Cell Line: NCI-H460) [7]
SCH 727965 + Dasatinib DCU3RBR SCH 727965 Malignant melanoma (Cell Line: A375) [7]
SCH 727965 + Dasatinib DCNLO3Y SCH 727965 Malignant melanoma (Cell Line: HT144) [7]
SCH 727965 + Dasatinib DCC56V2 SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [7]
SCH 727965 + Dasatinib DC2AJ5Q SCH 727965 Malignant melanoma (Cell Line: UACC62) [7]
SCH 727965 + Dasatinib DCS2U0L SCH 727965 Mesothelioma (Cell Line: MSTO) [7]
SCH 727965 + Dasatinib DCHH4ZL SCH 727965 Non small cell carcinoma (Cell Line: SKMES1) [7]
SCH 727965 + Dasatinib DCL76KL SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
SCH 727965 + Dasatinib DCO223Y SCH 727965 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
SCH 727965 + Dasatinib DCKW865 SCH 727965 Prostate carcinoma (Cell Line: LNCAP) [7]
SCH 727965 + Dasatinib DC36GW4 SCH 727965 Prostate carcinoma (Cell Line: VCAP) [7]
Sirolimus + Dasatinib DCLCMPI Sirolimus Astrocytoma (Cell Line: U251) [5]
Sirolimus + Dasatinib DC8UM98 Sirolimus Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Sirolimus + Dasatinib DCB3ZKI Sirolimus Clear cell renal cell carcinoma (Cell Line: A498) [5]
Sirolimus + Dasatinib DCKZF7N Sirolimus Carcinoma (Cell Line: RXF 393) [6]
Sirolimus + Dasatinib DC2IGLM Sirolimus Adenocarcinoma (Cell Line: HCT116) [7]
Sirolimus + Dasatinib DC9L277 Sirolimus Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Sirolimus + Dasatinib DCG8TAD Sirolimus Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
SY-1425 + Dasatinib DC7AK94 SY-1425 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
SY-1425 + Dasatinib DC9XWF4 SY-1425 Adenocarcinoma (Cell Line: NCIH23) [7]
SY-1425 + Dasatinib DCO4BQW SY-1425 Adenocarcinoma (Cell Line: HCT116) [7]
SY-1425 + Dasatinib DCJS7RU SY-1425 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Taxol + Dasatinib DCZEDLK Taxol Adenocarcinoma (Cell Line: COLO320DM) [5]
Taxol + Dasatinib DC37VKQ Taxol Adenocarcinoma (Cell Line: DLD1) [5]
Taxol + Dasatinib DCZTZN8 Taxol Adenocarcinoma (Cell Line: HT29) [5]
Taxol + Dasatinib DC4F3FE Taxol Astrocytoma (Cell Line: U251) [5]
Taxol + Dasatinib DCESKQH Taxol Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Taxol + Dasatinib DCILOAD Taxol Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Taxol + Dasatinib DCLDGY4 Taxol Breast carcinoma (Cell Line: ZR751) [6]
Taxol + Dasatinib DCA3ZY0 Taxol Breast carcinoma (Cell Line: OCUBM) [6]
Taxol + Dasatinib DCD6RC8 Taxol Carcinoma (Cell Line: OV90) [6]
Taxol + Dasatinib DC79KUD Taxol Carcinoma (Cell Line: EFM192B) [6]
Taxol + Dasatinib DCPTMXU Taxol Carcinoma (Cell Line: MDAMB436) [6]
Taxol + Dasatinib DCQAFKL Taxol Colon carcinoma (Cell Line: RKO) [6]
Taxol + Dasatinib DCSBLR2 Taxol Colon carcinoma (Cell Line: KM12) [6]
Taxol + Dasatinib DCGWRIZ Taxol Invasive ductal carcinoma (Cell Line: T-47D) [6]
Taxol + Dasatinib DC63YAU Taxol Adenocarcinoma (Cell Line: OVCAR3) [7]
Taxol + Dasatinib DCZHDHY Taxol Adenocarcinoma (Cell Line: A427) [7]
Taxol + Dasatinib DCQZVC2 Taxol Adenocarcinoma (Cell Line: NCIH520) [7]
Taxol + Dasatinib DCAWGUJ Taxol Germ cell tumour (Cell Line: PA1) [7]
Taxol + Dasatinib DCN9Z7Z Taxol Malignant melanoma (Cell Line: A375) [7]
Taxol + Dasatinib DCQ1RSD Taxol Malignant melanoma (Cell Line: LOX IMVI) [7]
Taxol + Dasatinib DCUZT9R Taxol Mesothelioma (Cell Line: MSTO) [7]
Taxol + Dasatinib DC50HLR Taxol Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Taxol + Dasatinib DCBMK0Y Taxol Non small cell carcinoma (Cell Line: SKMES1) [7]
Taxol + Dasatinib DCXLQ4B Taxol Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Taxol + Dasatinib DCREXZQ Taxol Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Thioguanine + Dasatinib DC0L22V Thioguanine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Thioguanine + Dasatinib DC265TP Thioguanine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Thioguanine + Dasatinib DCXIK11 Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [5]
Thioguanine + Dasatinib DCRXUFM Thioguanine Astrocytoma (Cell Line: U251) [5]
Thioguanine + Dasatinib DCF9S0G Thioguanine Astrocytoma (Cell Line: SNB-19) [5]
Thioguanine + Dasatinib DCXTUGZ Thioguanine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Thioguanine + Dasatinib DCAO5KS Thioguanine Chronic myelogenous leukemia (Cell Line: K-562) [5]
Thioguanine + Dasatinib DC799XW Thioguanine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Thioguanine + Dasatinib DC87694 Thioguanine Glioblastoma (Cell Line: SNB-75) [5]
Thioguanine + Dasatinib DC5SR7K Thioguanine Glioma (Cell Line: SF-539) [5]
Thioguanine + Dasatinib DCQBE8A Thioguanine Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Thioguanine + Dasatinib DC39CXJ Thioguanine Renal cell carcinoma (Cell Line: SN12C) [5]
Thioguanine + Dasatinib DCT7JA4 Thioguanine Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Thioguanine + Dasatinib DC402Q7 Thioguanine Carcinoma (Cell Line: MCF7) [6]
Thioguanine + Dasatinib DCA9V3J Thioguanine Colon adenocarcinoma (Cell Line: COLO 205) [6]
Thioguanine + Dasatinib DCFS8FU Thioguanine Adenocarcinoma (Cell Line: NCIH23) [7]
Thioguanine + Dasatinib DCX5GX1 Thioguanine Adenocarcinoma (Cell Line: SW-620) [7]
Thioguanine + Dasatinib DC5693D Thioguanine Adenocarcinoma (Cell Line: HCC-2998) [7]
Thioguanine + Dasatinib DC5U9YL Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [7]
Thioguanine + Dasatinib DCK83FV Thioguanine Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Thioguanine + Dasatinib DCV9LKC Thioguanine Lung adenocarcinoma (Cell Line: HOP-62) [7]
Thioguanine + Dasatinib DCTDHKH Thioguanine Lung adenocarcinoma (Cell Line: NCI-H522) [7]
Thioguanine + Dasatinib DCUU397 Thioguanine Malignant melanoma (Cell Line: UACC62) [7]
Thioguanine + Dasatinib DC05SG8 Thioguanine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Thioguanine + Dasatinib DCZC05B Thioguanine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Dasatinib DCWQF21 Topotecan Carcinoma (Cell Line: MDAMB436) [6]
Topotecan + Dasatinib DCG14VB Topotecan Colon carcinoma (Cell Line: RKO) [6]
Topotecan + Dasatinib DCK1CBI Topotecan Adenocarcinoma (Cell Line: CAOV3) [7]
Topotecan + Dasatinib DCGGTY9 Topotecan Adenocarcinoma (Cell Line: A427) [7]
Topotecan + Dasatinib DCMGSXR Topotecan Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Dasatinib DC665WP Topotecan Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + Dasatinib DCQZ368 Topotecan Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + Dasatinib DCZX7IT Topotecan Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + Dasatinib DCTEV8J Topotecan Adenocarcinoma (Cell Line: HCC-2998) [7]
Topotecan + Dasatinib DC6SF5V Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Dasatinib DCHYVVA Topotecan Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + Dasatinib DC5KDIG Topotecan Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Dasatinib DCDIODJ Topotecan Anaplastic large cell lymphoma (Cell Line: SR) [7]
Topotecan + Dasatinib DCBNJZS Topotecan Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Topotecan + Dasatinib DCTPCTE Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Dasatinib DCKBQ8Y Topotecan Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [7]
Topotecan + Dasatinib DCYZ3XQ Topotecan Germ cell tumour (Cell Line: PA1) [7]
Topotecan + Dasatinib DCJ9IQR Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [7]
Topotecan + Dasatinib DCCR1L5 Topotecan Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Topotecan + Dasatinib DCNRRB4 Topotecan Malignant melanoma (Cell Line: A375) [7]
Topotecan + Dasatinib DC70MC4 Topotecan Malignant melanoma (Cell Line: UACC62) [7]
Topotecan + Dasatinib DCY20TC Topotecan Mesothelioma (Cell Line: MSTO) [7]
Topotecan + Dasatinib DCUK2AM Topotecan Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + Dasatinib DCXPPPJ Topotecan Prostate carcinoma (Cell Line: VCAP) [7]
Tosyl-l-arginine methyl ester + Dasatinib DCN9MLQ Tosyl-l-arginine methyl ester Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [5]
Trifluridine + Dasatinib DCY9KQ0 Trifluridine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Trifluridine + Dasatinib DCR2CVS Trifluridine Glioma (Cell Line: SF-539) [5]
Trifluridine + Dasatinib DC6V8F3 Trifluridine Glioma (Cell Line: SF-295) [5]
Trifluridine + Dasatinib DC34YQM Trifluridine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Uracil mustard + Dasatinib DCPBKJE Uracil mustard Astrocytoma (Cell Line: SNB-19) [5]
Uracil mustard + Dasatinib DCYTCOL Uracil mustard Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Uracil mustard + Dasatinib DCNGRAU Uracil mustard Glioblastoma (Cell Line: SNB-75) [5]
Uracil mustard + Dasatinib DCYBCXO Uracil mustard Glioma (Cell Line: SF-539) [5]
Uracil mustard + Dasatinib DCHF70E Uracil mustard Glioma (Cell Line: SF-295) [5]
Uracil mustard + Dasatinib DCXN5AA Uracil mustard Adenocarcinoma (Cell Line: HCT116) [7]
Uracil mustard + Dasatinib DCRSSI7 Uracil mustard Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Uracil mustard + Dasatinib DCTAU5X Uracil mustard High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Uracil mustard + Dasatinib DCT7MUE Uracil mustard High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Uracil mustard + Dasatinib DC1UK7Y Uracil mustard Lung adenocarcinoma (Cell Line: NCI-H522) [7]
Uracil mustard + Dasatinib DCBBDX5 Uracil mustard Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Uracil mustard + Dasatinib DC8O86G Uracil mustard Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Vandetanib + Dasatinib DCBEG8M Vandetanib Invasive ductal carcinoma (Cell Line: T-47D) [6]
Vandetanib + Dasatinib DC4PPVB Vandetanib Adenocarcinoma (Cell Line: DU-145) [7]
Vandetanib + Dasatinib DCWF94E Vandetanib Adenocarcinoma (Cell Line: A549) [7]
Vandetanib + Dasatinib DCK78E9 Vandetanib Astrocytoma (Cell Line: U251) [7]
Vandetanib + Dasatinib DCPW8MY Vandetanib Chronic myelogenous leukemia (Cell Line: K-562) [7]
Vandetanib + Dasatinib DC1TZL7 Vandetanib Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Vandetanib + Dasatinib DC77FDE Vandetanib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Vandetanib + Dasatinib DCHVBO8 Vandetanib Glioma (Cell Line: SF-268) [7]
Vandetanib + Dasatinib DC1QVP9 Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Vandetanib + Dasatinib DC0Z9M2 Vandetanib Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Vandetanib + Dasatinib DCJZ1TI Vandetanib Lung adenocarcinoma (Cell Line: HOP-62) [7]
Vandetanib + Dasatinib DCHFNKX Vandetanib Lung adenocarcinoma (Cell Line: EKVX) [7]
Vandetanib + Dasatinib DCELTOI Vandetanib Lung adenocarcinoma (Cell Line: MDA-MB-231) [7]
Vandetanib + Dasatinib DC0FS0P Vandetanib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Vandetanib + Dasatinib DCF61KY Vandetanib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Vandetanib + Dasatinib DCMSHIR Vandetanib Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Vandetanib + Dasatinib DCSGR37 Vandetanib Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Vandetanib + Dasatinib DCNT9ZE Vandetanib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Vandetanib + Dasatinib DC2ARX8 Vandetanib Prostate carcinoma (Cell Line: PC-3) [7]
Vandetanib + Dasatinib DC0PI67 Vandetanib Renal cell carcinoma (Cell Line: UO-31) [7]
Vemurafenib + Dasatinib DC3R18O Vemurafenib Adenocarcinoma (Cell Line: HT29) [7]
Vemurafenib + Dasatinib DC0X46Y Vemurafenib Astrocytoma (Cell Line: U251) [7]
Vemurafenib + Dasatinib DC6U4PB Vemurafenib Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Vemurafenib + Dasatinib DCYNB8X Vemurafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Vemurafenib + Dasatinib DCBYW7P Vemurafenib Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Vemurafenib + Dasatinib DCG5R3Y Vemurafenib Glioma (Cell Line: SF-539) [7]
Vemurafenib + Dasatinib DCPRQRW Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [7]
Vemurafenib + Dasatinib DCVHDG9 Vemurafenib Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Vemurafenib + Dasatinib DC3OSEM Vemurafenib Lung adenocarcinoma (Cell Line: HOP-62) [7]
Vemurafenib + Dasatinib DCCLNZH Vemurafenib Malignant melanoma (Cell Line: LOX IMVI) [7]
Vemurafenib + Dasatinib DCSR88L Vemurafenib Melanoma (Cell Line: UACC-257) [7]
Vemurafenib + Dasatinib DC3K01L Vemurafenib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Vemurafenib + Dasatinib DC4LVPG Vemurafenib Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Vemurafenib + Dasatinib DC78VIG Vemurafenib Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Vemurafenib + Dasatinib DC6DP2F Vemurafenib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Vemurafenib + Dasatinib DCVX7IQ Vemurafenib Prostate carcinoma (Cell Line: PC-3) [7]
Vinblastine + Dasatinib DCK80M5 Vinblastine Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinblastine + Dasatinib DCLXJV2 Vinblastine Adenocarcinoma (Cell Line: DLD1) [5]
Vinblastine + Dasatinib DCUYJY2 Vinblastine Germ cell tumour (Cell Line: PA1) [5]
Vinblastine + Dasatinib DCUAMO9 Vinblastine Malignant melanoma (Cell Line: A375) [5]
Vinblastine + Dasatinib DCU06SH Vinblastine Malignant melanoma (Cell Line: UACC62) [5]
Vinblastine + Dasatinib DCKS62T Vinblastine Mesothelioma (Cell Line: MSTO) [5]
Vinblastine + Dasatinib DCNIIED Vinblastine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinblastine + Dasatinib DCMGHD5 Vinblastine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinblastine + Dasatinib DC71XEL Vinblastine Prostate carcinoma (Cell Line: VCAP) [5]
Vinblastine + Dasatinib DCTZ56Y Vinblastine Breast carcinoma (Cell Line: OCUBM) [6]
Vinblastine + Dasatinib DCXBHET Vinblastine Carcinoma (Cell Line: OV90) [6]
Vinblastine + Dasatinib DCNKI39 Vinblastine Carcinoma (Cell Line: MDAMB436) [6]
Vinblastine + Dasatinib DCDHJ3P Vinblastine Rectal adenocarcinoma (Cell Line: SW837) [6]
Vincristine + Dasatinib DCPE3KK Vincristine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vincristine + Dasatinib DC7IQKZ Vincristine Glioma (Cell Line: SF-539) [5]
Vincristine + Dasatinib DCYI0WG Vincristine Glioma (Cell Line: SF-268) [5]
Vincristine + Dasatinib DCJRRCC Vincristine Malignant melanoma (Cell Line: LOX IMVI) [5]
Vincristine + Dasatinib DCAQ79Y Vincristine Renal cell carcinoma (Cell Line: SN12C) [5]
Vinorelbine + Dasatinib DCT9EID Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Vinorelbine + Dasatinib DCI8VHA Vinorelbine Breast carcinoma (Cell Line: KPL1) [6]
Vinorelbine + Dasatinib DC15FNF Vinorelbine Breast carcinoma (Cell Line: OCUBM) [6]
Vinorelbine + Dasatinib DC2YWKN Vinorelbine Carcinoma (Cell Line: OV90) [6]
Vinorelbine + Dasatinib DCV82VU Vinorelbine Carcinoma (Cell Line: MDAMB436) [6]
Vinorelbine + Dasatinib DCRZ6RO Vinorelbine Colon carcinoma (Cell Line: RKO) [6]
Vinorelbine + Dasatinib DCPFQKB Vinorelbine Invasive ductal carcinoma (Cell Line: T-47D) [6]
Vinorelbine + Dasatinib DC149M7 Vinorelbine Rectal adenocarcinoma (Cell Line: SW837) [6]
Vinorelbine + Dasatinib DCU2YWY Vinorelbine Adenocarcinoma (Cell Line: A427) [7]
Vinorelbine + Dasatinib DCZN5T7 Vinorelbine Adenocarcinoma (Cell Line: COLO320DM) [7]
Vinorelbine + Dasatinib DCRP4WH Vinorelbine Adenocarcinoma (Cell Line: DLD1) [7]
Vinorelbine + Dasatinib DCTZI33 Vinorelbine Adenocarcinoma (Cell Line: HT29) [7]
Vinorelbine + Dasatinib DCKTIIP Vinorelbine Germ cell tumour (Cell Line: PA1) [7]
Vinorelbine + Dasatinib DCX8S1N Vinorelbine Malignant melanoma (Cell Line: A375) [7]
Vinorelbine + Dasatinib DCTCI2U Vinorelbine Mesothelioma (Cell Line: MSTO) [7]
Vinorelbine + Dasatinib DCAOOFD Vinorelbine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Vinorelbine + Dasatinib DCEDYWC Vinorelbine Prostate carcinoma (Cell Line: LNCAP) [7]
Vismodegib + Dasatinib DCZGJO1 Vismodegib Adenocarcinoma (Cell Line: A549) [7]
Vismodegib + Dasatinib DCHIVWI Vismodegib Adenocarcinoma (Cell Line: HT29) [7]
Vismodegib + Dasatinib DC8U39Z Vismodegib Astrocytoma (Cell Line: U251) [7]
Vismodegib + Dasatinib DCEJU5Y Vismodegib Chronic myelogenous leukemia (Cell Line: K-562) [7]
Vismodegib + Dasatinib DCBS24R Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Vismodegib + Dasatinib DCR5F5Q Vismodegib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Vismodegib + Dasatinib DCMDG3W Vismodegib Glioma (Cell Line: SF-268) [7]
Vismodegib + Dasatinib DCL22PL Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Vismodegib + Dasatinib DC94Y37 Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Vismodegib + Dasatinib DCSO9GJ Vismodegib Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Vismodegib + Dasatinib DCW1ZV0 Vismodegib Lung adenocarcinoma (Cell Line: MDA-MB-231) [7]
Vismodegib + Dasatinib DC2JJUE Vismodegib Lung adenocarcinoma (Cell Line: NCI-H522) [7]
Vismodegib + Dasatinib DCZK60U Vismodegib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Vismodegib + Dasatinib DCS3S4V Vismodegib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Vismodegib + Dasatinib DCXE00E Vismodegib Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Vismodegib + Dasatinib DCKPPR1 Vismodegib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Vismodegib + Dasatinib DC11Q2V Vismodegib Prostate carcinoma (Cell Line: PC-3) [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1296 DrugCom(s)
27 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
ABL001 + Dasatinib DCS6LC8 ABL001 Chronic Myelogenous Leukemia [8]
Azacitidine + Dasatinib DC04YOF Azacitidine Acute Myeloid Leukemia [9]
Capecitabine + Dasatinib DCRE56F Capecitabine Advanced Breast Cancer [10]
Crizotinib + Dasatinib DC6G7W1 Crizotinib Diffuse Intrinsic Pontine Glioma [11]
Crizotinib + Dasatinib DCMIGX4 Crizotinib Advanced Cancers [12]
Cyclosporin A + Dasatinib DCEEZBO Cyclosporin A Accelerated Phase Chronic Myelogenous Leukemia [13]
Daunorubicin + Dasatinib DCS4SCA Daunorubicin Acute Myeloid Leukemia (AML) [14]
Decitabine + Dasatinib DC8FHQX Decitabine Leukemia [15]
Docetaxel + Dasatinib DC27E5H Docetaxel Metastatic Prostate Cancer [16]
Erlotinib + Dasatinib DCFLAUJ Erlotinib Lung Cancer [17]
Fulvestrant + Dasatinib DCRJZ0O Fulvestrant Advanced Breast Cancer [18]
Gemcitabine + Dasatinib DCIK2D1 Gemcitabine Refractory Solid Tumors [19]
Idarubicin + Dasatinib DC679I9 Idarubicin Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities [20]
Ixabepilone + Dasatinib DCDJY6C Ixabepilone Metastatic Breast Cancer [21]
Ixabepilone + Dasatinib DCU2K0O Ixabepilone Solid Tumor [22]
Letrozole + Dasatinib DCYLKRD Letrozole Metastatic Breast Cancer [23]
Leucovorin + Dasatinib DCMZ23K Leucovorin Pancreatic Cancer Metastatic [24]
Leuprolide + Dasatinib DC2YU6A Leuprolide Prostate Cancer [25]
Osimertinib + Dasatinib DCI069L Osimertinib EGFR Gene Mutation [26]
Temozolomide + Dasatinib DC5KORW Temozolomide Brain and Central Nervous System Tumors [27]
Valproic Acid + Dasatinib DCQR8UB Valproic Acid Solid Tumors [28]
Zoledronate + Dasatinib DCTIUK9 Zoledronate Breast Cancer [29]
Darolutamide + Dasatinib DCSSVAO Darolutamide Metastatic Prostate Cancer [30]
Erlotinib + Dasatinib DCPFSHH Erlotinib Diffuse Intrinsic Pontine Glioma [31]
Everolimus + Dasatinib DC3C3QB Everolimus Glioma [32]
Everolimus + Dasatinib DC6C0HO Everolimus Diffuse Intrinsic Pontine Glioma [31]
Imatinib + Dasatinib DCI18X3 Imatinib Chronic Myeloid Leukemia [33]
------------------------------------------------------------------------------------
⏷ Show the Full List of 27 DrugCom(s)

References

1 Dasatinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5678).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
5 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
7 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
8 ClinicalTrials.gov (NCT02081378) A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
9 ClinicalTrials.gov (NCT05042531) Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia
10 ClinicalTrials.gov (NCT00452673) Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
11 ClinicalTrials.gov (NCT01644773) Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
12 ClinicalTrials.gov (NCT01744652) Dasatinib and Crizotinib in Advanced Cancer
13 ClinicalTrials.gov (NCT01426334) Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate
14 ClinicalTrials.gov (NCT00850382) Dasatinib (Sprycel? in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
15 ClinicalTrials.gov (NCT01498445) An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
16 ClinicalTrials.gov (NCT00439270) Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
17 ClinicalTrials.gov (NCT00826449) Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
18 ClinicalTrials.gov (NCT00754325) Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
19 ClinicalTrials.gov (NCT00598091) A Phase I/Expansion Study of Dasatinib
20 ClinicalTrials.gov (NCT01876953) Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
21 ClinicalTrials.gov (NCT00924352) Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
22 ClinicalTrials.gov (NCT00717704) Solid Tumors Using Ixabepilone and Dasatinib
23 ClinicalTrials.gov (NCT00696072) Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
24 ClinicalTrials.gov (NCT01652976) Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
25 ClinicalTrials.gov (NCT00860158) Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
26 ClinicalTrials.gov (NCT02954523) Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
27 ClinicalTrials.gov (NCT00869401) Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
28 ClinicalTrials.gov (NCT00495872) Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
29 ClinicalTrials.gov (NCT00566618) Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
30 ClinicalTrials.gov (NCT04925648) Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
31 ClinicalTrials.gov (NCT02233049) Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
32 ClinicalTrials.gov (NCT03352427) Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
33 ClinicalTrials.gov (NCT03193281) KISS Study: Kinase Inhibition With Sprycel Start up